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1. PreAMbLe
For many years, dyslipidaemias failed to re-
ceive the attention they deserve, both in Poland 
and across the world. In many cases, the most 
common recommendation given to patients suf-
fering from lipid disorders was to change their 
diet and lifestyle. Despite multiple educational ef-
forts undertaken by medical societies in Poland, 
including the signatories of the Guidelines, the 
knowledge of patients about this independent 
risk factor continues to be very limited even today. 
As a result, there are nearly 20 million hypercho-
lesterolaemic patients in Poland [1]. Furthermore, 
there are no medical (lipid) clinics specializing in 
the treatment of lipid disorders, and existing out-
patient clinics are not usually dedicated specifi-
cally to dyslipidaemias, but metabolic disorders 
and/or endocrine conditions. Not uncommonly, 
patients receive treatment in cardiac outpatient 
clinics. The existing state of affairs stems part-
ly from systemic constraints, which pose a  hin-
drance to the establishment of a network of lipid 
outpatient clinics – even though a total of 70 lipi-
dologists have already been certified by the Polish 
Lipid Association (PoLA). This is precisely why the 
problem of familial hypercholesterolaemia (FH) in 
Poland was not recognized as significant for many 
years. Few physicians were able to consider low 
density lipoprotein cholesterol (LDL-C) concentra-
tions in excess of 190 mg/dl (4.9 mmol/l) or total 
cholesterol (TC) concentrations of 290 mg/dl (7.5 
mmol/l) and more as potentially caused by genet-
ically conditioned disease and, taking the matter 
further, classify patients presenting with such dis-
orders into high and very high cardiovascular risk 
groups [2]. This is why the treatment of patients 
with the most severe lipid disorders with aphere-
sis is practically non-existent in Poland, with only 
three treatment centres available to patients. In 
contrast, in neighbouring countries (Germany, 
Czech Republic), nationwide FH registries have 
been kept for many years. Germany, in addition, 
has the largest number of medical centres offering 
apheresis treatment in Europe. 
It was first noted about a dozen years ago in 
the estimation of long-term (20-year) risk or life-
time risk that dyslipidaemias represented an inde-
pendent risk factor for cardiovascular (CV) events. 
It thus follows that optimal effective treatment of 
lipid disorders is as important as the therapy of di-
abetes or arterial hypertension [3]. What is more, 
even if dyslipidaemia treatment is undertaken, 
further challenges must be faced such as failure 
to use/prescribe statins at doses corresponding to 
the level of CV risk (the situation may affect as 
much as 80% of all treated patients), discontinu-
ation of therapy [4], lack of effective combination 
treatment aimed at reducing residual risk or fail-
ure to ensure appropriate management of unde-
sirable treatment-related effects [3, 5]. 
In view of the situation outlined above, the 
PoLA, the College of Family Physicians in Poland 
(CFPiP) and the Polish Cardiac Society (PCS) have 
jointly identified a need to draft the first guide-
lines regulating the management of dyslipidae-
mias and addressed to family physicians, as they 
are usually the first to diagnose lipid disorders 
and they are largely responsible for the initial 
therapeutic decisions and for the continuation of 
lipid-lowering therapy (LLT). 
2. InTroDuCTIon
Dyslipidaemias are the most common yet the 
least well-controlled risk factor for cardiovascular 
disease (CVD) in Poland [1]. The main modifiable 
risk factors for atherosclerosis and its complica-
tions including ischaemic heart disease (IHD), 
stroke and peripheral artery disease (PAD) are: 
smoking, type 2 diabetes, arterial hypertension, 
inappropriate diet and eating habits, inadequate 
physical activity as well as the resulting over-
weight and obesity [6]. As shown by epidemio-
logical studies conducted in Poland, there is a na-
tionwide growth in the above risk factors (with 
the exception of smoking in the majority of age 
groups), which is attributable to the increasing 
prevalence of poor eating habits and sedentary 
lifestyle [1]. The elimination of risk factors rep-
resents one of the greatest challenges to be faced 
in the domain of public health. In order to rise 
to up to the challenge, wide-ranging population 
prevention measures are needed. However, family 
physicians as well as other health professionals 
(cardiologists, internists) have a special responsi-
bility towards high-risk patients. The group defi-
nitely comprises a considerable proportion of dys-
lipidaemia patients. Consequently, dyslipidaemia 
management should be an element of a broader 
strategy targeted at lowering total CV risk and, 
hence, reducing mortality, morbidity and disability 
associated with CVD.
3. orGAnIzATIon oF GuIDeLIneS 
Members of the Steering Committee responsi-
ble for developing the Guidelines were selected by 
the PoLA, CFPiP and PCS as experts in the treat-
ment of patients suffering from dyslipidaemias. 
The Steering Committee performed a  detailed 
review of published evidence regarding the man-
agement of dyslipidaemia including the diagnosis, 
treatment, prevention and critical evaluation of 
diagnostic and therapeutic procedures including 
the assessment of the benefit-to-risk ratio. The 
level of evidence and the strength of recommen-
dations with respect to particular management 
options were weighed and graded according to 
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widely recognized classifications which are out-
lined in Tables I and II. To meet the needs of the 
target group and ensure the ease of use of the 
Guidelines, the class and strength of recommen-
dations were applied only to the key provisions, 
particularly those raising the most doubts and 
questions, and having the greatest practical sig-
nificance for dyslipidaemia therapy. Each chapter 
is additionally summarized in frames, with a focus 
on points to be remembered by physicians as well 
as key recommendations. 
Experts from the panels writing and review-
ing the Guidelines filled in declaration of inter-
est forms with respect to all relationships which 
might be seen as either actual or potential sources 
of conflicts of interest. Following the final approval 
of the contents of the Guidelines, the final version 
of the document is scheduled for parallel publica-
tion in Archives of Medical Science (recommenda-
tion by PoLA), Lekarz Rodzinny (official journal of 
CFPiP), Kardiologia Polska (official journal of PCS), 
and Lekarz POZ (official journal of PSFM). 
Family physicians and medical professionals of 
other specialties treating patients with lipid dis-
orders are encouraged to take full account of the 
Guidelines in the process of evaluating the clini-
cal status of their patients, and determining and 
implementing medical strategies for the preven-
tion, diagnosis and treatment of dyslipidaemias. 
However, the Guidelines do not override in any 
way the individual responsibility of physicians to 
make appropriate and accurate decisions taking 
into account the condition of a given patient, in 
consultation with that patient, and, where neces-
sary, with the patient’s guardian or carer. It is also 
the responsibility of health professionals to verify 
the rules and regulations applicable to drugs and 
devices at the time of their prescription/use.
4.  ePIDeMIoLoGy oF DySLIPIDAeMIAS  
In PoLAnD 
Dyslipidaemias are the most widespread CV 
risk factor, which has also been demonstrated in 
Polish observational cohort (screening) studies. 
The key studies together with study sample selec-
tion methods and study periods are summarized 
in Table III. 
Depending on the study sample selection, the 
incidence of dyslipidaemias in Poland is estimated 
at 60–70% of the population over 18 years of age 
[7, 8]. The initial data obtained on the prevalence 
of hyperlipidaemia (Pol-MONICA study) revealed 
hypercholesterolaemia in slightly more than 70% 
of women and nearly 73% of men [9]. In the study, 
a  higher proportion of men (60%) than women 
(53%) was shown to have LDL levels higher than 
the normal range [9]. Reduced concentrations of 
high density cholesterol (HDL) were noted in near-
ly 2% of women and 10% of men, and elevated 
concentrations of triglycerides (TG) were present 
in 6% of women and 21% of men [9]. In the next 
study (SPES), hypercholesterolaemia was noted in 
nearly 56% of the subjects (58% of women and 
52% of men) [10]. The results, however, were not 
nationwide in scope, and were limited to the total 
area of the former Polish provinces: Warszawskie 
with Tarnobrzeskie (Pol-MONICA), and Katowickie 
with Bielskie (SPES). 
Table I. Classes of recommendations included in the Guidelines
recommendation class Definition Suggested applicability
Class I  There is scientific evidence and/or general agreement 
that a given treatment/procedure is beneficial, useful 
and effective
Is recommended/is indicated
Class II Data from scientific studies are ambiguous and/or there 
is a divergence of opinion about the usefulness/efficacy 
of a given treatment/procedure
Class IIa The weight of evidence/opinion is in favour of the 
usefulness/efficacy of a given treatment/procedure
Should be considered
Class IIb Available evidence/opinion does not corroborate the 
usefulness/efficacy of a given treatment/procedure
May be considered
Class III There is scientific evidence and/or general agreement 
that a given treatment/procedure is not useful/effective, 
and in some cases may be harmful
Is not recommended
Table II. Levels of evidence
Level of evidence A Data derived from multiple randomized clinical studies or meta-analyses 
Level of evidence b Data derived from a single randomized clinical trial or large non-randomized trials
Level of evidence C Consensus of opinion of experts and/or data derived from small studies, retrospective 
studies and registries 
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Subsequent data on the prevalence of dys-
lipidaemia in Poland are based on two random 
study samples encompassing the entire coun-
try, i.e. NATPOL III PLUS and WOBASZ studies. In 
NATPOL, the incidence of hypercholesterolaemia 
was estimated at 59.5% in men and 62% in wom-
en. In WOBASZ, the respective figures were 67% 
and 64% [11, 12]. The NATPOL study found that 
the LDL-C level was above the normal range in 
almost identical proportions of men and women 
(55%) [11]. In WOBASZ, increased concentrations 
of LDL-C were observed in 60% of men and 55% of 
women [12]. The proportions of patients with re-
duced HDL-C concentrations in the NATPOL study 
were 17% for men and 6% for women. In WOBASZ, 
the figures were 15% and 17%, respectively [11, 
12]. Based on the NATPOL study, hypertriglyce-
ridaemia in Poland was shown to occur in 30% 
of the subjects, with a  higher incidence in men 
than in women (38% vs. 23%) [5]. In WOBASZ, in-
creased TG concentrations were observed in 31% 
of men and 20% of women [12].
Based on the US guidelines the National Choles-
terol Education Program Adult Treatment Panel III 
(NCEP ATPIII), a significant prevalence of lipid disor-
ders was also determined in three nationwide Pol-
ish studies: LIPIDOGRAM2003, LIPIDOGRAM2004 
and LIPIDOGRAM2006. The final databases for 
the studies included a  total of over 49,000 pa-
tients treated by primary care physicians [13–15]. 
In LIPIDOGRAM2003, the mean concentrations 
of lipid profile parameters were: TC – 228 mg/
dl (5.9 mmol/l), LDL-C – 140 mg/dl (3.6 mmol/l), 
HDL-C – 57 mg/dl (1.5 mmol/l), TG – 156 mg/dl 
(1.8 mmol/l) [13]. Hypercholesterolaemia > 200 mg/ 
dl (> 5.2 mmol/l) was found in 72% of the sub-
jects, with a higher incidence among women than 
in men (76% vs. 67%). Elevated LDL-C concentra-
tions > 160 mg/dl (4.1 mmol/l) were noted in 28% 
of the study subjects, more frequently in women 
than in men (30% vs. 24%). Reduced HDL-C con-
centrations < 40 mg/dl (1.0 mmol/l) were observed 
in 6% of the study subjects, 12% of men and 3% 
of women. Increased TG concentrations > 200 mg/
dl (2.3 mmol/l) were revealed in 22% of the sub-
jects, more frequently in men than in women (26% 
vs. 19%) [13]. Mean concentrations of different 
lipid profile parameters and proportions of values 
above the normal range in consecutive studies – 
LIPIDOGRAM2004 [14] and LIPIDOGRAM2006 [15] 
– are shown in Figure 1 and Table IV. 
In the next study, NATPOL 2011, the mean con-
centrations of lipid profile parameters for men 
and women respectively were: TC – 197.1 mg/dl 
(5.1 mmol/l) and 198.6 mg/dl (5.1 mmol/l), LDL-C 
– 123.6 mg/dl (3.2 mmol/l) and 123.7 mg/dl (3.2 
mmol/l), HDL-C – 45.8 mg/dl (1.2 mmol/l) and 54.1 
mg/dl (1.4 mmol/l), TG – 140.9 mg/dl (1.6 mmol/l) 
and 104.0 mg/dl (1.2 mmol/l). Lipid profile param-
eters in excess of the normal range were noted in 
the following proportions of subjects: TC > 190 mg 
(4.9 mmol/l) – 54.3% (54.3% of men and 54.4% of 
women), LDL-C > 115 mg/dl (3.0 mmol/l) – 57.8 % 
(58.3% of men and 57.3% of women), HDL-C 
< 40 mg/dl (1.0 mmol/l) – 32.5% of men, HDL-C 
< 45 mg/dl (1.2 mmol/l) – 22% of women, 
TG > 150 mg/dl (1.7 mmol/l) – 21,1% (28.4% of 
men and 14.0% of women) [1].
Table III. Polish epidemiological studies on dyslipidaemia by method of subject selection for observation
Studies with random sample selection  
from the general population
Studies involving active  
primary care patients
Acronym year(s) of the study Acronym year(s) of the study
Pol-MONICA 1984–1993 SPES 1997
NATPOL III PLUS 2002 POLSCREEN 2002
WOBASZ 2003–2005 LIPIDOGRAM2003 2003
NATPOL 2011 2011 LIPIDOGRAM2004 2004
WOBASZ II 2013–2014 LIPIDOGRAM2006 2006
LIPIDOGRAM 5 YEARS 2004–2010
LIPIDOGRAM2015 2015–2016
 TC LDL HDL TG
 LIPIDOGRAM2004         LIPIDOGRAM2006
Figure 1. Mean concentrations of lipid profile param-
eters in LIPIDOGRAM2004 and LIPIDOGRAM2006 
M
ea
n 
co
nc
en
tr
at
io
ns
 o
f 
lip
id
 
pr
of
ile
 p
ar
am
et
er
s 
[m
g/
dl
]
250
200
150
100
50
0
224221
130132
64 58
146148
M. Banach, P. Jankowski, J. Jóźwiak, B. Cybulska, A. Windak, T. Guzik, A. Mamcarz, M. Broncel, T. Tomasik, et al.
6 Arch Med Sci 1, February / 2017
In the WOBASZ II study, which was conducted 
2 years later, hypercholesterolaemia was found 
in 70.3% of men and 64.3% of women aged 
> 20 years (67.1% of the total study population). 
Furthermore, hypertriglyceridaemia with normal 
cholesterol concentrations was observed in 5.6% 
of men and 2.4% of women. Reduced HDL-C con-
centrations with normal TC and TG levels were 
found in 5.1% of men and 7.3% of women. Over-
all, at least one dyslipidaemia type was detected 
in 81.0% of men and 74.0% of women. As much 
as 60.6% of subjects with hypercholesterolaemia 
were not aware of the fact, and only 6% received 
effective treatment and achieved reference con-
centrations of their lipid profile parameters [16].
LIPIDOGRAM 5 YEARS, a prospective Polish na-
tionwide cohort study (n = 1,841) covering a pe-
riod of 5 years (2004–2010), conducted in a pop-
ulation of primary care patients treated due to 
dyslipidaemia, found that the lipid profile parame-
ters were not effectively reduced in approximately 
50% of subjects with TC concentrations above the 
normal range and in over 30% of patients with el-
evated LDL-C and TG concentrations [7]. Evidence 
for the lack of efficacy of dyslipidaemia treatment 
was also supplied by the earlier screening studies: 
LIPIDOGRAM2004 and LIPIDOGRAM2006 [17–20]. 
Inadequate control of hypercholesterolaemia 
was also shown in patients after hospitalization 
for IHD within the framework of the Cracow Pro-
gramme for Secondary Prevention of Ischaemic 
Heart Disease [21]. Target LDL-C concentrations 
< 70 mg/dl (< 1.8 mmol/l) were noted in only 28.1% 
of the patients. In 71.9%, 38.6%, 24.4% and 10.3% 
of the subjects, however, LDL-C concentrations 
were ≥ 70 mg/dl (≥ 1.8 mmol/l), ≥ 100 mg/dl (≥ 2.5 
mmol/l), ≥ 115 mg/dl (≥ 3.0 mmol/l) and ≥ 160 mg/dl 
(≥ 4.0 mmol/l), respectively [21]. Studies conduct-
ed over the past 20 years suggest that the success 
rate in achieving the recommended LDL-C level in 
patients with IHD has not changed in relation to 
the end of the 20th century [22]. The success rate 
in achieving target LCL-C levels in patients who are 
treated in primary care does not deviate signifi-
cantly from the success rate in patients declaring 
that their treatment is prescribed by physicians in 
specialist cardiac outpatient clinics [22]. 
Preliminary, still unpublished results of the re-
cently completed study LIPIDOGRAM2015 show ele-
vated TC concentrations > 190 mg/dl (> 4.9 mmol/l) 
in 58% of active primary care patients aged 
> 18 years. LDL-C concentrations > 115 mg/dl 
(> 3.0 mmol/l) were seen in 61% of the patients, 
and reduced HDL-C levels (< 40 mg/dl (< 1.0 mmol/l) 
in men and < 45 mg/dl (< 1.2 mmol/l) in wom-
en) were determined in 14% of the study sub-
jects. Increased concentrations of TG > 150 mg/dl 
(> 1.7 mmol/l) were observed in 33% of the patients.
5.  DySLIPIDAeMIAS AS A rISk FACTor  
AnD STrATIFICATIon oF CV rISk 
5.1. Lipids as a risk factor
Available results of scientific research point to 
a  direct link between the concentrations of TC, 
LDL-C and non-HDL-C (total cholesterol concen-
tration minus HDL cholesterol concentration) and 
the risk of myocardial infarction (MI), stroke and 
fatal CVD [3, 6]. Large meta-analyses suggest that 
a 1 mmol/l difference in TC concentration is associ-
ated with an increase in the risk of death from IHD 
by 120% in patients aged 40–49 years, by 75% in 
key PoInTS To reMeMber
Based on the assumption that a family physi-
cian in his/her standard medical practice pro-
vides care to about 2,500 patients including 
over 75% of adults [1], and the estimated prev-
alence of dyslipidaemia in Poland is 60–70% in 
the population over 18 years of age, it can be 
inferred that every physician has under his/her 
care about 1,100–1,300 people with dyslipidae-
mias including up to 10 patients with familial 
hypercholesterolaemia [23, 24].
Table IV. Percentages of lipid profile parameter concentrations above the normal range in LIPIDOGRAM2004 and 
LIPIDOGRAM2006 studies
LIPIDoGrAM2004 LIPIDoGrAM2006
Concentration criteria % Concentration criteria %
TC > 200 mg/dl 69 TC > 200 mg/dl 66
LDL-C > 160 mg/dl 21 LDL-C > 160 mg/dl 22
LDL-C > 130 mg/dl 48 LDL-C > 130 mg/dl 49
LDL-C > 100 mg/dl 79 LDL-C > 100 mg/dl 79
HDL-C < 40 mg/dl 4 HDL-C < 40 mg/dl 7
TG > 200 mg/dl 18 TG > 200 mg/dl 19
TG > 150 mg/dl 35 TG > 150 mg/dl 37
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patients aged 50–59 years, by 47% in patients aged 
60–69 years, by 27% in patients aged 70–79 years 
and by 18% in patients aged 80–89 years [25]. The 
above data, however, should not be interpreted as 
suggesting that the risk of hypercholesterolaemia in 
elderly people is lower. In fact, due to a significantly 
higher CV risk, hypercholesterolaemia is associated 
with a greater number of CV events and deaths in 
the elderly population than in younger age groups 
[6]. The correlation of LDL-C and non-HDL-C con-
centrations with patient prognosis has been shown 
to persist even after incorporating other risk factors 
including HDL-C and TG concentrations [26]. 
Whereas high LDL-C and non-HDL-C concen-
trations are correlated with an increased CV risk, 
a high concentration of HDL-C is associated with 
a risk reduction. The association has been shown 
to remain significant even after taking into ac-
count other risk factors including concentrations 
of the non-HDL-C fraction and TG [26]. The role of 
low HDL-C concentration as a risk marker is less 
prominent in patients with atherosclerosis and in 
the group of patients treated with statins. It must 
also be emphasized that all therapeutic interven-
tions aimed at reducing the (residual) CV risk as 
a result of increase in HDL-C concentration have 
given negative results to date, which may be at-
tributable to the so-called dysfunctional HDL-C oc-
curring in patients with conditions accompanied 
by an increased inflammatory process and/or oxi-
dative stress (e.g. obesity, smoking, diabetes, IHD, 
chronic kidney disease (CKD)) [6, 27].
A high TG concentration is associated with an 
elevated risk of serious cardiovascular events. 
Some analyses, however, show that the associa-
tion is no longer evident when other risk factors 
are taken into account – including in particular 
HDL-C and non-HDL-C concentrations [26]. Avail-
able studies also suggest that high TG concentra-
tions are linked to increased concentrations of the 
most atherogenic fraction of small dense LDL cho-
lesterol (sdLDL-C) [6]. 
Even though the relationship between lipids 
and CV risk forms a continuum, for practical rea-
sons certain cut-off points have been adopted to 
define concentrations recognized as abnormal. For 
LDL-C, the concentration depends on the total CV 
risk (Table V). In low or moderate risk patients, high 
concentrations of LDL-C refer to values ≥ 115 mg/ 
dl (≥ 3.0 mmol/l), in high risk patients – to levels 
≥ 100 mg/dl (≥ 2.6 mmol/l), and in very high risk 
patients ≥ 70 mg/dl (≥ 1.8 mmol/l) [6]. 
HDL-C concentrations of < 40 mg/dl (< 1.0 mmol/l) 
in men and < 45 mg/dl (< 1.2 mmol/l) in women 
are considered abnormal. Similarly, TG concentra-
tions of > 1.7 mmol/l (> 150 mg/dl) are regarded 
as abnormal. It must be stressed that insofar as the 
cut-off points defined for LDL-C are recognized ther-
apeutic targets, HDL-C and TG concentrations given 
above may not be regarded as therapeutic targets 
due to a limited scientific basis [6].
5.2. Stratification of CV risk
At present, total CV risk assessment is the ba-
sis for appropriate management in terms of CVD 
prevention and therapy [28]. In accordance with 
current guidelines of scientific societies, total CV 
risk should guide decisions on the intensity of 
treatment, including the introduction of pharma-
cological treatment of hypercholesterolaemia [6]. 
Total CV risk assessment also facilitates the edu-
cation of patients [6]. In 2015, the Polish Cardiac 
Society published updated risk estimation charts 
dedicated to the Polish population – Pol-SCORE 
2015 (Figure 2) [29]. 
The first step in preparing treatment recom-
mendations for a  patient with dyslipidaemia is 
Table V. Definitions of cardiovascular risk groups [6]
Very high risk •	 Cardiovascular disease (CVD) documented by invasive or non-invasive testing (abnormal ECG 
waves, coronary angiography, nuclear medicine methods, stress echocardiography, ultrasound 
imaging of carotid plaques), previous acute coronary syndrome (ACS), coronary revascularization 
procedure, ischaemic stroke or transient cerebral ischaemia, or peripheral artery disease (PAD)
•	 Type 1 or 2 diabetes with at least one CV risk factor and/or target organ complications (such as 
urinary albumin excretion in the range of 30–300 mg/day)
•	 Severe CKD (GFR < 30 ml/min/1.73 m2)
•	 10-year risk of fatal CVD calculated by Pol-SCORE ≥ 10%
High risk •	 Markedly elevated single risk factors such as familial hypercholesterolaemia or severe 
hypertension
•	 Diabetes without CV risk factors or target organ complications (some patients with type 1 
diabetes without significant risk factors and complications may be classified into the low or 
moderate risk groups)
•	 Moderate CKD (GFR 30–59 ml/min/1.73 m2)
•	 10-year risk of fatal cardiovascular disease calculated by Pol-SCORE ≥ 5% but < 10%
Moderate risk •	 10-year risk of fatal cardiovascular disease calculated by Pol-SCORE ≥ 1% but < 5%
Low risk •	 10-year risk of fatal cardiovascular disease calculated by Pol-SCORE < 1%
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Figure 2. SCORE charts calibrated for the Polish population (Pol-SCORE 2015). The numbers in the charts represent 
the 10-year risk of fatal cardiovascular disease [29]
Women Men
Non-smokers Non-smokersSmokers Smokers
Sy
st
ol
ic
 b
lo
od
 p
re
ss
ur
e 
[m
m
 H
g]
Age
70
65
60
55
50
40
≥ 15%
10–14%
5–9%
3–4%
2%
1%
< 1%
310
270
230
190
150
180
160
140
120
180
160
140
120
180
160
140
120
180
160
140
120
180
160
140
120
180
160
140
120
 4    5     6     7     8  4   5    6      7    8
mg/dl
 4   5   6     7     8  4  5   6      7   8
Total cholesterol [mmol/l]
Pol-SCore 2015
10-year risk of fatal cardiovascular disease
PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016
Arch Med Sci 1, February / 2017 9
determining the CV risk category to which the 
patient belongs (Table V). It needs to be stressed 
that patients with a history of CV events or with 
a  documented cardiac or vascular disease are 
a priori classified as being at very high risk. Also, 
Pol-SCORE charts should not be used to assess CV 
risk in patients with diabetes or CKD (with glomer-
ular filtration rate (GFR) < 60 min/1.73 m2). Such 
patients should be directly stratified into appropri-
ate risk groups. In all remaining cases, CV risk is 
assessed on the basis of Pol-SCORE 2015 charts 
(Figure 2), taking into account the age and gender 
of patients, as well as their smoking status, TC con-
centration and systolic blood pressure (SBP). This 
is how the 10-year risk of fatal CVD is estimated. 
Table VI presents risk factors and conditions 
associated with an increased CV risk, which are 
not included in the Pol-SCORE 2015 chart. It is 
advisable to take them into consideration partic-
ularly when the CV risk estimated using the chart 
is on the borderline between two categories (e.g. 
amounts to 5%). In such cases, considering the 
HDL-C concentration or the presence of depression 
moves the patient into a higher risk category (e.g. 
with concomitant depression or low HDL-C con-
centration) or a lower risk group (e.g. with the ab-
sence of depression or high HDL-C concentration). 
Pol-SCORE charts can be a useful tool for pa-
tient education. With their aid it is possible to 
show patients in an approachable manner how 
their CV risk level will drop after introducing an ef-
fective treatment for a particular risk factor. In the 
near future, the Polish Cardiac Society will pub-
lish on its website a total CV risk score calculator 
which will allow a more accurate estimation of CV 
risk compared to the charts. 
6.  reCoMMenDATIonS For  
THe ASSeSSMenT oF ConSTITuenT 
PArAMeTerS oF THe LIPID ProFILe  
AnD ITS LIMITATIonS
An effective diagnosis of lipid disorders de-
pends to a large extent on the knowledge of spe-
cific lipid profile parameters, recommended nor-
mal ranges and effects on CV risk. In daily medical 
practice, the most commonly evaluated lipid pro-
file parameters include TC, LDL-C, HDL-C and TG. 
Recent years have also seen a multitude of reports 
on the role of estimating non-HDL-C, lipoprotein(a) 
(Lp(a)), apolipoprotein B (ApoB), apolipoprotein A1 
(ApoA1), LDL particles (LDL-P) as well as TC/HDL-C 
and TG/HDL-C ratios, and many others [30].
Screening tests should be performed in individ-
uals with at least one risk factor for CVD (e.g. arte-
rial hypertension, nicotine dependence syndrome, 
diabetes, overweight, adverse family history) and 
in all men > 40 years old and all women > 50 years 
old – as well as patients with CVD, CKD or autoim-
mune disease (see Chapter 16). If the lipid profile 
is within the normal range, it is indicated to repeat 
the test at least every 3–5 years. In patients with 
hypercholesterolaemia, screening should be per-
formed on a yearly basis after achieving the target 
concentration of LDL-C. Screening for lipid disor-
ders should also be performed in children aged 
> 2 years with a  family history of dyslipidaemia 
including FH or premature CVD, and in children 
with other risk factors. The optimal age range for 
conducting lipid metabolism tests is 9–11 years. 
If the lipid concentrations are within the normal 
key PoInTS To reMeMber
There is a  close independent correlation be-
tween the concentration of cholesterol, primar-
ily LDL-C, and the development of atherosclero-
sis and the risk of serious CV events. 
reCoMMenDATIonS
•	 Every patient should be evaluated to deter-
mine total CV risk for the purpose of ensur-
ing appropriate patient education and mak-
ing decisions on the intensity of treatment, 
including the rationale to introduce pharma-
cological treatment of dyslipidaemia.
•	 Pol-SCORE 2015 should be used for the esti-
mation of total CV risk of patients in primary 
prevention (see Chapter 7). 
Table VI. Factors increasing CV risk which are not 
included in Pol-SCORE [6, 29]
Sedentary lifestyle
Central obesity
Psychosocial factors including:
Low socioeconomic status
Social deprivation and low social support
Workplace and family stress
Depression (chronically depressed mood)
Diseases and conditions associated with risk increase: 
Low HDL-C concentration
High triglyceride concentration
Some autoimmune diseases (psoriasis, rheumatoid 
arthritis)
Periodontitis 
Obstructive sleep apnoea
Family history of premature cardiovascular disease 
HIV
Atrial fibrillation
Left ventricular hypertrophy
Psychiatric disorders
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range between the ages of 9 and 11, tests should 
be repeated at the age of about 18 years, as lipid 
profile results obtained at this age demonstrate 
the highest prognostic value for lipid levels over 
the next two decades of life. 
6.1. LDL cholesterol
Studies conducted in recent years have shown 
that the determination of LDL-C plays an essential 
role in the diagnosis of dyslipidaemias. LDL-C is 
recognized as a  lipid profile parameter which al-
lows reliable stratification of CV risk, even though 
there are ongoing debates as to the preferred 
method of LDL-C determination (Friedewald for-
mula, direct method, modified Friedewald formu-
las, newly proposed Martin formula) and condi-
tions of LDL-C testing (under fasting conditions or 
not).  The most common method of LDL-C deter-
mination is the Friedewald formula: 
(in mg/dl): LDL-C = TC – HDL-C – (TG/5) 
and (in mmol/l): LDL-C = TC – HDL-C – (TG/2.2).
However, it should be noted that the method 
may involve methodological measurement errors, 
since the LDL-C determination formula necessi-
tates analyses of three separate lipid parameters: 
TC, HDL-C and TG. Also, the method should not 
be used if the TG level exceeds 400 mg/dl (> 4.5 
mmol/l) or if fasting conditions cannot be ensured 
(in such cases non-HDL-C should preferably be de-
termined). Measurement errors may also accom-
pany very low LDL-C levels [31, 32]. Available stud-
ies show that the direct method of determining 
LDL-C seems comparable to the Friedewald for-
mula and carries no risk of error in the situations 
described above, with the exception of hypertri-
glyceridaemia and very low LDL-C levels (with po-
tential differences of ±15 mg/dl) [32]. In such cas-
es, non-HDL-C and ApoB tests can be considered 
[32]. The most recent studies indicate that the 
Martin formula of determining LDL-C may be the 
most effective method, free from the limitations 
outlined above, however further studies are need-
ed to verify the results obtained to date [33]. Re-
cent data also suggest that lipid parameter tests 
performed under fasting or non-fasting conditions 
are comparable in terms of CV risk prediction, par-
ticularly with regard to TC, LDL-C and HDL-C. Food 
ingestion, however, has a significant effect on TG, 
as results obtained under non-fasting conditions 
are on average 27 mg/dl (0.3 mmol/l) higher than 
under fasting conditions [32]. 
6.2. Other lipid profile parameters 
Total cholesterol tests are essentially insignif-
icant nowadays, as they are only used in deter-
mining the SCORE risk and the level of non-HDL-C, 
and in diagnosing patients with familial hypercho-
lesterolaemia (in cases involving very high values, 
particularly over 290 mg/dl (7.6 mmol/l)) [32]. 
The concentration of HDL-C is currently irrele-
vant for predicting CV risk, and available studies 
with nicotinic acid (niacin) or cholesteryl ester 
transfer protein (CETP) inhibitors have failed to 
demonstrate any role of HDL-C in reducing re-
sidual risk [31]. Furthermore, studies conducted 
in recent years have revealed a  high complexity 
of HDL-C metabolism including the effects of in-
flammation, oxidative stress or glycation process 
on HDL-C functionality and generation of dysfunc-
tional HDL-C which may display proatherogenic 
properties [34].
The determination of triglycerides may be 
of high relevance in patients with diabetes and 
metabolic syndrome accompanied by atherogen-
ic dyslipidaemia, i.e. a  condition characterized 
by high TG levels coexisting with low concentra-
tions of HDL-C and high concentrations of sdLDL 
(the most atherogenic LDL-C fraction). Available 
prospective and genetic studies as well as me-
ta-analyses have shown indisputably that high 
TG concentration is an independent risk factor 
for CV events [32].
From the practical (clinical) point of view, special 
attention should also be focused on non-HDL-C 
(calculated as the difference between TC and 
HDL-C) which is used for the assessment of total 
plasma concentration of atherogenic lipoproteins 
(very low density lipoprotein (VLDL) cholesterol, 
VLDL remnants, intermediate-density lipoproteins 
(IDL), LDL and Lp(a)). The determination of the pa-
rameter involves no additional costs, and its values 
are at least as predictive as the LDL-C level. Conse-
quently, it seems valid to recommend the determi-
nation of non-HDL-C in all lipid profile tests, partic-
ularly in high and very high risk patients who have 
achieved LDL-C targets (Table VII) [32].
In recent years, especially following research 
into proprotein convertase subtilisin/kexin type 9 
(PCSK9) inhibitors, attention has focused on the 
special role of Lp(a) as an independent (of other 
risk factors: arterial hypertension, LDL-C, diabe-
tes or smoking) predictor of CV risk. Due to the 
fact that the concentration of Lp(a) is largely ge-
netically conditioned, high Lp(a) levels are often 
found in individuals with a family history of high 
concentrations of this lipid parameter often re-
sulting in early CV events or fatal CVD [35, 36]. 
As a  consequence, Lp(a) determination should 
always be considered in symptomatic individuals 
with no other risk factors and with a family histo-
ry of early-onset CVD of atheromatous origin and 
in patients with high CV risk levels (Table VIII). 
Every Lp(a) value above the 80th percentile 
(50 mg/dl) should be regarded as a significant CV 
risk factor [32].
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7.  DySLIPIDAeMIA TreATMenT TArGeTS 
(rISk-reLATeD TArGeT VALueS)
The greatest importance is attributed to the 
achievement of the therapeutic target for LDL-C 
[32]. It is a result of several facts which have been 
well-established for a  long time now. Firstly, both 
inter- and intrapopulation epidemiological studies 
reveal a  direct proportional relationship between 
the concentration of the lipoprotein and the risk of 
CV events, mainly of the coronary type [6, 32]. Sec-
ondly, clinical observations show that individuals 
with high LDL-C concentrations are under high risk 
of premature CVD [6]. One example is genetically 
determined FH [2]. Thirdly, hypercholesterolemia 
induced by a cholesterol-rich diet may lead to ath-
erosclerosis in rabbits. Fourthly, cholesterol found in 
atheromatous plaques is known to come from LDL 
[37]. Finally, a decrease in LDL-C level causes a pro-
portional reduction of CVD risk, as shown in multi-
ple studies investigating statins [6, 31, 32]. The last 
finding concludes the theory on the causal role of 
LDL-C for the development of atherosclerosis.
The therapeutic target for LDL-C depends on 
the individual risk of fatal CVD during a 10-year 
period (Table IX) [6, 32]. The higher the risk, the 
lower the LDL-C level should be (according to the 
theory: “the lower the better”). 
There are no data suggesting that low LDL-C 
concentrations (even < 25 mg/dl (0.6 mmol/l)) are 
harmful. Also, it should be strongly stressed that 
after achieving the therapeutic target for LDL-C, 
statin treatment is continued at the same doses 
[6, 32]. This is because, based on available data, 
the strategy continues to reduce the risk of CV 
events, while statin discontinuation or dose reduc-
tion after target achievement may be associated 
with atheromatous plaque instability and an in-
creased risk of CV event [6, 32, 37]. 
Non-HDL-C and/or ApoB concentration can be 
a  secondary target of therapy especially in pa-
tients with high TG levels [6, 32]. Non-HDL-C is 
a measure of TC content in all atherogenic lipo-
proteins, i.e. LDL, VLDL and so-called remnants. 
Remnants are partially catabolized lipoproteins 
Table VII. Recommendations for determining lipid profile parameters as treatment targets in prevention of isch-
aemic heart disease
recommendations Class  
of recommendation
Level 
of evidence
LDL-C is recommended as the primary target of therapy I A
Total cholesterol determination should be considered where determination 
of other parameters is not available 
IIa A
Non-HDL-C determination should be considered as a secondary target  
of therapy,
•	particularly	in	patients	who	have	achieved	target	LDL-C	levels
IIa
I
B
B
ApoB should be considered as a secondary target of therapy where its 
determination is possible 
IIa B
HDL-C is not recommended as a target of therapy III A
Table VIII. Populations in which Lp(a) determina-
tion/monitoring should be considered
Patients with premature cardiovascular disease
Patients with familial hypercholesterolaemia 
Patients with a history of premature CVD or elevated 
Lp(a) concentration 
Patients with repeated CV events despite optimal 
lipid-lowering therapy
Patients with 10-year risk of fatal CVD ≥ 5% (based on 
Pol-SCORE)
reCoMMenDATIonS
•	 LDL-C is recommended as the primary target 
of treatment, and non-HDL-C determination 
should be considered as a secondary target 
of therapy. 
•	 HDL-C is not recommended as a  target of 
therapy. 
•	 Lp(a) determination should always be con-
sidered in patients with premature CVD 
(often without other CV risk factors) and/or 
with a family history of CVD. 
key PoInTS To reMeMber
•	 The Friedewald formula for determining 
LDL-C should not be used when TG concen-
trations exceed 400 mg/dl (> 4.5 mmol/l) 
and when LDL values are low (≤ 100 mg/dl 
(2.6 mmol/l)). 
•	 Lipid parameter tests performed under fast-
ing or non-fasting conditions are compara-
ble particularly with regard to TC, LDL-C and 
HDL-C. Food ingestion, however, has a signifi-
cant effect on TG: results obtained under non- 
fasting conditions are on average 27 mg/dl 
(0.3 mmol/l) higher than under fasting con-
ditions.
•	 TG determination can be of great signifi-
cance in patients with diabetes and/or met-
abolic syndrome, which is accompanied by 
atherogenic dyslipidaemia.
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transporting triglycerides, i.e. VLDL and chylomi-
crons, and have proportionally higher cholesterol 
content [32]. Remnants play a similar role in the 
development of atherosclerosis as LDL-C [32]. In-
creased concentrations of remnants can accom-
pany combined hyperlipidaemia, diabetes, meta-
bolic syndrome and CKD. ApoB is an indicator of 
the number of atherogenic lipoprotein particles. 
Every particle of LDL, VLDL and remnants contains 
an ApoB particle. However, experts from the Euro-
pean Society of Cardiology (ESC) and other soci-
eties responsible for developing the most recent 
guidelines for the prevention of CVD, similarly to 
the authors of the guidelines for the management 
of dyslipidaemias issued by the ESC and the Euro-
pean Atherosclerosis Society (EAS), have conclud-
ed that there is no sufficient evidence showing 
ApoB to be a better prognostic factor for risk than 
LDL-C (or non-HDL-C) [6, 32].
Observational studies demonstrate that hyper-
triglyceridaemia is an independent risk factor for 
CVD (weaker than hypercholesterolaemia), how-
ever no therapeutic targets are available for that 
lipid because of lack of evidence coming from ran-
domized controlled trials (RCTs) that would serve 
as a basis for establishing such targets [32, 38]. 
Nevertheless, TG concentrations of > 150 mg/dl 
(> 1.7 mmol/l) under fasting conditions are still 
recognized as a marker of increased risk, and TG 
values of > 200 mg/dl (> 2.3 mmol/l) (during statin 
treatment) – as an indication to consider an addi-
tional treatment with fenofibrate [32, 38].
Based on observational studies, a  low HDL-C 
concentration is a risk factor for the development 
of ischaemic heart disease. However, it has not 
been established indisputably whether it rep-
resents a  causal factor [34]. Studies conducted 
to date on drugs increasing the concentration of 
HDL-C have failed to demonstrate a reduction in 
the risk of CV events [6, 26, 32]. Consequently, 
HDL-C is not a  target of therapy, however based 
on available epidemiological study results, HDL 
concentrations < 40 mg//dl (< 1.0 mmol/l) in men 
and < 45 mg/dl (< 1.2 mmol/l) in women can be 
considered as markers of elevated risk [6, 32].
reCoMMenDATIonS
•	 The primary target in the treatment of dys-
lipidaemias is to reduce the LDL-C level.
•	 The targets of therapy depend on the risk of 
CV event. The higher the risk, the lower the 
LDL-C level should be aimed at (see Table IX).
•	 After achieving the LDL-C target, statin ther-
apy should be continued at the same doses. 
•	 In primary prevention, Pol-SCORE-based 
risk estimation should be performed (see 
Chapter 5), with the exception of patients: 
(a) with a history of CV event; (b) peripheral 
artery atherosclerosis; (c) carotid atheroma-
tous plaques; (d) severe arterial hyperten-
sion; (e) suspected primary hypercholes-
terolaemia; (f) diabetes; (g) chronic kidney 
disease. Such patients are at very high or 
high risk regardless of their gender and age, 
and do not require an assessment based on 
the Pol-SCORE chart.
Table IX. Recommendations for target LDL-C and non-HDL-C and ApoB concentrations [6, 32]
risk Target lipid concentration
Low: risk of fatal cardiovascular disease < 1% based on Pol-SCORE •	 LDL-C < 115 mg/dl (< 3 mmol/l)
•	 Non-HDL-C < 145 mg/dl (< 3.8 mmol/l)Moderate: risk of fatal cardiovascular disease ≥ 1% and < 5% 
based on Pol-SCORE
High:
Single strong risk factor (familial dyslipidaemia, severe arterial 
hypertension)
•	 LDL-C < 100 mg/dl (< 2.6 mmol/l) or 
reduction by ≥ 50% if the baseline value is 
100–190 mg/dl (2.6–4.9 mmol/l)
•	 Non-HDL-C < 130 mg/dl (< 3.3 mmol/l)*
•	 Apo B < 100 mg/dl**
Type 1 or 2 diabetes without an additional risk factor or organ 
damage
Moderate chronic kidney disease (GFR: 30–59 ml/min/1.73 m2)
 Risk of fatal cardiovascular disease ≥ 5% and < 10% based on 
Pol-SCORE
Very high:
Diagnosed cardiovascular disease •	 LDL-C < 70 mg/dl (< 1.8 mmol/l) or 
reduction by ≥ 50% if the baseline value is 
70–135 mg/dl (1.8–3.5 mmol/l)
•	 Non-HDL-C < 100 mg/dl (< 2.6 mmol/l)*
•	 Apo B < 80 mg/dl**
Type 1 or 2 diabetes with ≥ 1 risk factor or organ damage  
(e.g. microalbuminuria)
Severe chronic kidney disease (GFR < 30 ml/min/1.73 m2)
Risk of fatal cardiovascular disease ≥ 10% based on Pol-SCORE
*See Chapter 6 + non-HDL-C applies to patients with elevated TG concentrations, so the assessment of the parameter should be taken into 
consideration in diabetes, metabolic syndrome or chronic kidney disease where the diseases are accompanied by hypertriglyceridaemia; 
**Not a part of routine tests in the family physician practice.
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8. reSIDuAL rISk 
Residual risk refers to the probability of adverse 
events which persists despite taking measures 
aimed at risk minimization. In patients with CVD, 
measures reducing mortality and morbidity risks 
are geared towards the control of modifiable risk 
factors for the development of atherosclerosis. 
The residual risk in a dyslipidaemia patient refers 
to the risk of death, MI and stroke, which persists 
in that patient despite ongoing dyslipidaemia 
treatment and achievement of therapeutic targets 
(e.g. for LDL-C) [39]. Available studies investigating 
statins show that a decrease in LDL-C by an aver-
age of 28% causes a 31% reduction in relative risk, 
leaving a residual risk of 69%, i.e. higher than that 
eliminated in the course of treatment [40].
In the prevention of CVD and treatment of dys-
lipidaemias, crucial importance is attributed to 
lipid-lowering drugs, predominantly statins, which 
have demonstrated a high efficacy in these indi-
cations. However, the risk remains even in individ-
uals who, following intensive statin therapy, have 
achieved a decrease in LDL-C concentration to the 
target level [41]. Some patients could benefit from 
a decrease in residual risk through an earlier in-
troduction of statin treatment, others from more 
intensive therapy and yet others – from combi-
nation therapy. Hence family physicians play an 
important role in the early diagnosis of dyslipidae-
mias, introduction of lifestyle changes and opti-
mization of pharmacological therapy in patients. 
Other identified risk factors, such as smoking, 
excessive alcohol consumption, hypertension, el-
evated glycaemia values, overweight or obesity, 
and low physical activity levels, also require ap-
propriate management [42]. Reducing the level of 
residual risk probably can also be accomplished 
through an effect on various factors: psychological 
(e.g. relief of stress, therapy for depression), social 
(e.g. assistance in gaining support and preventing 
social exclusion) and environmental (e.g. improve-
ment in living and working conditions). Health 
professionals, quality of medical care provided to 
patients, organization of the healthcare system 
and health policy are all known to have a role in 
decreasing residual risk [40].
International initiatives stress that family phy-
sicians in their practice should pay a  closer at-
tention to atherogenic dyslipidaemia (elevated 
TG and LDL-C concentrations, low HDL-C concen-
tration) occurring in patients with diabetes and 
metabolic syndrome. Atherogenic dyslipidaemia 
frequently remains undiagnosed and untreated, 
resulting in failure to achieve the potential for risk 
reduction [43]. So far, RCTs with fibrates and nic-
otinic acid have failed to demonstrate a reduction 
in residual risk linked to a TG decrease and HDL-C 
increase. The only drug which has been shown to 
decrease the level of residual risk (by 6%) relat-
ed to an additional LDL-C reduction is ezetimibe 
in combination with simvastatin [44]. Studies are 
ongoing to determine the effects of CEPT inhib-
itors (anacetrapib) and PCSK9 inhibitors (evolo-
cumab, alirocumab) [41].
9.  non-PHArMACoLoGICAL PreVenTIon 
AnD TreATMenT oF DySLIPIDAeMIAS
One of the fundamental goals defined by ESC 
for the management of CV risk is the control of 
dyslipidaemia. The central target in controlling 
dyslipidaemia is to reduce the concentrations of 
LDL-C, i.e. the most atherogenic cholesterol frac-
tion. According to the current guidelines, the first 
step involves estimating the patient’s CV risk and 
full lipid profiling. On that basis, the management 
strategy which is recommended in a  particular 
patient group should be selected. Based on the 
guidelines issued by the European Association 
for Cardiovascular Prevention and Rehabilitation 
(EACPR) in June 2016 [6], lifestyle modifications 
are recommended in all patients, while lipid-low-
ering drugs are indicated only in selected clinical 
situations. Similar recommendations are included 
in the ESC/EAS Guidelines for the management of 
dyslipidaemias issued in August 2016 [32]. The 
effects of non-pharmacological modifications on 
different lipoprotein fractions are summarized in 
Table X. 
9.1. Effect on TC and LDL-C levels
The dietary factor with the strongest impact 
on reducing the levels of total cholesterol and 
low-density cholesterol fraction is a  decrease in 
the consumption of saturated fatty acids (SFAs) 
and trans fats [6, 45]. Functional foods containing 
phytosterols have been shown to have a  similar 
impact on TC and LDL-C [6, 32]. For every 1% of 
key PoInTS To reMeMber
•	 In dyslipidaemia treatment, especially in 
patients with diagnosed heart disease and 
classified as being at high risk, aside from 
statins, other lipid-lowering drugs (which 
further decrease the LDL-C and TG levels) 
and combination treatment may be consid-
ered to reduce residual risk.
•	 In patients who have achieved LDL-C tar-
gets, residual risk is linked to a number of 
risk factors including arterial hypertension, 
hyperglycaemia, inflammatory diseases and 
inappropriate lifestyle. Consequently, target-
ed treatment also taking into account the 
above-mentioned disorders should be intro-
duced. 
M. Banach, P. Jankowski, J. Jóźwiak, B. Cybulska, A. Windak, T. Guzik, A. Mamcarz, M. Broncel, T. Tomasik, et al.
14 Arch Med Sci 1, February / 2017
the dietary energy derived from SFAs which is re-
placed with monounsaturated fatty acids (MUFAs), 
plasma LDL-C levels decrease by 1.6 mg/dl; and 
substitution with polyunsaturated fatty acids 
(PUFAs) results in a LDL-C decrease of 2.0 mg/dl. 
The replacement of SFAs with carbohydrates 
translates into the lowest reduction of LDL-C 
(1.2 mg/dl) [6, 32]. Optimal dietary substitutes 
for products with a  high SFA content are carbo-
hydrate foods rich in fibre. Dietary fibre actively 
lowers the absorption of fats in the intestines. In 
addition, the majority of fibre-rich plant products 
have a  low energy density which facilitates the 
maintenance of the recommended balance of cal-
ories. Body weight reduction, similarly to physical 
activity, fails to influence LDL-C in a  meaningful 
way: a drop in LDL-C concentration by 8 mg/dl is 
observed for every 10 kg of weight loss. Impor-
tantly, however, both excess body weight and low 
levels of physical activity represent independent 
risk factors for CVD. Furthermore, a lifestyle inter-
vention in this scope contributes significantly to 
a TG decrease and HDL-C increase [6, 32].
9.2. Effect on TG levels
The most effective interventions aimed at re-
ducing TG levels include body weight reduction, 
minimization of alcohol intake, reduced consump-
tion of monosaccharides, as well as regular phys-
ical activity [6]. Body weight loss improves insulin 
sensitivity in tissues, which has a direct impact on 
the plasma concentrations of TG. Achieving a nor-
mal body weight in some patients is difficult due 
to an oversupply of calories contained in alcohol. 
Excessive alcohol intake (over 10–30 g/day) sig-
nificantly elevates the concentration of TG [6, 32, 
45]. Replacing SFAs with unsaturated fatty acids 
significantly improves insulin sensitivity. Unfortu-
nately, a dietary approach based on natural foods 
rarely ensures an adequate intake of unsaturated 
fatty acids, which is why n-3 PUFA supplements 
may be utilized [45].
In addition, TG levels are closely linked to a per-
turbation of carbohydrate metabolism. Excessive 
monosaccharide intake leads to a  significant in-
crease in TG concentrations. The best effects in 
reducing the fraction can be achieved through 
the consumption of foods with a  low glycaemic 
index (e.g. raw fruit and vegetables, coarse grits, 
oat bran, cottage cheese and fish). The glycaemic 
index permits the identification and differentia-
tion of foods with fast and slow rates of glucose 
absorption into the blood plasma. Fibre-rich plant 
foods make it possible to reduce the glycaemic 
index of food products through the absorption of 
glucose and its gradual release during intestinal 
transit [6, 45]. 
9.3. Effect on HDL-C level
Appropriately functional HDL have a protective 
effect with respect to atherogenesis. Unfortunate-
ly, pharmacological attempts to increase the levels 
of these lipoproteins have failed to yield satisfac-
tory results in terms of CV risk reduction, so the 
Table X. Impact of non-pharmacological changes on different lipid profile parameters
Impact of specific non-pharmacological changes TC and LDL-C TG HDL-C
Reduced dietary trans fats +++
A
– +++
A
Reduced dietary saturated fats +++
A
– –
Increased dietary fibre ++
A
– –
Functional foods enriched with phytosterols ++
A
– –
Reduced alcohol intake – +++
A
Moderate intake 
is acceptable
Regular physical activity +
B
++
A
+++
A
Reduced intake of mono-and disaccharides – ++
B
+–
C
Reduced excessive body weight ++
A
+++
A
++
A
Red yeast rice supplements ++
A
– –
Supplements containing omega 3 acids – ++
A
–
A, B, C – levels of evidence. The strength of effect achieved with a particular intervention is marked with ‘+’ or ‘–’ in the following manner: 
+++, pronounced effect, ++ less evident effect, + small effect and – no effect. 
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only tools available today are based on insights 
from behavioural medicine [34, 45]. The most 
prominent increase in HDL-C is observed following 
a reduction in the dietary intake of trans fats. In ad-
dition, trans unsaturated fats lead to an increase 
in LDL-C levels. A  HDL-C increase is observed in 
response to an increased consumption of SFAs. 
Unfortunately, the increase is also associated with 
a rise in LDL-C, which ultimately fails to produce 
a beneficial effect in terms of minimizing CV risk. 
It should be stressed that the substitution of fats 
for carbohydrates as energy sources is associated 
with a significant decrease in HDL-C. However, no 
such effect has been observed to accompany the 
substitution of energy sources for complex carbo-
hydrates and foods with high fibre content (with 
a low glycaemic index) [6, 32]. 
One of the HDL-C-inducing dietary habits is 
alcohol consumption. However, this applies ex-
clusively to moderate alcohol consumption (up to 
30 g/day in men and 20 g/day in women), whereas 
alcohol abuse ranks among risk factors for a num-
ber of diseases. Due to the risk of developing al-
cohol addiction and the fact that alcohol produces 
detrimental effects, alcohol intake should not be 
recommended to patients. Weight reduction is also 
known to have a beneficial influence on HDL-C con-
centrations: an approximately 0.4 mg/dl increase in 
HDL-C is observed for every 1 kg decrease in body 
weight. The same effect has been observed for 
aerobic physical activity. An energy expenditure of 
about 1000 kcal translates into an increase in the 
HDL-C level by about 3 mg/dl [32, 45]. 
9.4.  Role of nutraceuticals and functional 
foods 
Functional foods
Functional foods perform a potentially import-
ant functional role supporting the achievement 
of therapeutic goals with respect to the concen-
trations of TC and individual lipid fractions. At 
present, the most thoroughly investigated and 
the most effective are food products containing 
phytosterols. The section below outlines only 
a  few selected nutraceuticals with documented 
lipid-lowering properties. 
Phytosterols and stanols 
The principal phytosterols are sitosterol, camp-
esterol and stigmasterol. They occur naturally in 
vegetable oils, vegetables, fresh fruit, whole grain 
products and legumes [6, 32]. They are also added 
to some margarines and yoghurts. The daily con-
sumption of 2 g of phytosterols or stanols (syn-
thesized from plant sterols; naturally occurring in 
fruit, nuts, grains and vegetable oils) can effectively 
lower LDL-C and TC levels by about 7–10% [6, 46]. 
MUFAs and PUFAs
Special attention in this group should be fo-
cused on n-3 unsaturated fatty acids. Ingested 
in the amount of about 2–3 g/day, they can re-
duce TG levels by about 25–30% [32, 45]. Howev-
er, such supplementation can only translate into 
a  small (of about 5%) increase in LDL-C concen-
trations. The use of n-3 PUFA is recommended in 
the treatment of hypertriglyceridaemia in patients 
with very high TG concentrations as an adjuvant 
to pharmacological treatment. 
Red yeast rice
The mechanism of pigments contained in fer-
mented rice is identical to that in statins. This 
is due to the fact that monacolin K contained in 
red yeast rice is chemically identical to lovastatin 
[45]. It should be noted, though, that commercial-
ly available products containing monacolin K may 
vary in the dose of the compound, which will have 
an impact on the strength of effect. The products, 
however, can be a  good solution for early phar-
macologic treatment of dyslipidaemia in patients 
who are ineligible for statin therapy.
9.5. Role of healthy lifestyle
Some of the more common risk factors for dys-
lipidaemia, which are widespread in the Polish 
population include overweight and obesity [1, 11]. 
It is therefore proposed that the achievement of 
appropriate body weight (body mass index (BMI) 
of 18.5–24.9 kg/m2) should constitute one of the 
targets of the strategy to maintain normal lipo-
protein concentrations [6]. In addition to BMI, an-
other important factor to consider is the patient’s 
waist circumference. Irrespective of BMI values in 
the normal range, an increased waist circumfer-
ence (men ≥ 94 cm; women ≥ 80 cm) is a factor 
determining a higher risk of CVD.
The development of healthy eating habits 
should involve not only an appropriate balance 
between calorie intake and expenditure but also 
good proportions of basic nutrients. Fatty acids 
should not account for more than 30% of energy 
supply, and SFAs should not exceed 10% of total 
energy supply in dyslipidaemia-free individuals, 
while patients with lipid disorders should have 
a  reduced dietary intake of SFAs (to maximum 
7%) [6]. Optimally, SFAs in the daily diet should 
be substituted for MUFAs and PUFAs, which can 
be achieved with diets based on plant products. 
This method of shaping dietary habits is consis-
tent with the most recent food pyramid published 
by the World Health Organization (WHO). Eating 
habits which are based on plant products also pro-
vide a high amount of dietary fibre and a reduced 
intake of simple sugars. Complex carbohydrates 
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should represent up to 55% of total energy supply. 
Dietary carbohydrates should be dominated by 
complex sugars, while simple sugars (i.e. mono- 
and disaccharides) should not exceed 10% of total 
energy supply [6]. 
Lifestyle medicine is one of the most important 
constituent elements of dyslipidaemia prevention 
and treatment. The crucial role here is played by 
modifications of dietary habits, physical activity 
and supplementation based on functional foods. 
In the light of the current Guidelines, lifestyle 
modifications should be encouraged in each pa-
tient group [6, 32] as an intrinsic element of dys-
lipidaemia treatment. 
10.  PHArMACoLoGICAL TreATMenT  
oF DySLIPIDAeMIA 
10.1. Statins
Lipid-lowering drugs, including statins, along 
with their history, mechanism of action, usage, 
side effects and clinical efficacy, have recently 
been described in a  detailed study [46]. Statins 
have been in clinical use for 30 years. The two 
most powerful drugs from this group, atorvastatin 
and rosuvastatin, are predominantly used nowa-
days. Statins inhibit hydroxymethylglutaryl-CoA 
(HMG-CoA) reductase, which is a key enzyme for 
the synthesis of cholesterol in hepatocytes. As 
a result, an increase in the activity of LDL recep-
tors (LDLR) on the cells is noted, together with 
an increased clearance of lipoproteins containing 
apolipoprotein B-100, i.e. LDL and VLDL remnants 
(including IDL). In comparative studies, atorvasta-
tin and rosuvastatin used for 6 weeks at a dose 
reCoMMenDATIonS
•	 Non-pharmacological modifications are rec-
ommended in all dyslipidaemia patients. 
•	 The intake of saturated fatty acids should be 
reduced to < 10% of total energy supply and 
to < 7% in dyslipidaemia patients.
•	 Trans-unsaturated fatty acids of natural or-
igin should provide < 1% of all consumed 
calories. Trans-unsaturated fatty acids of in-
dustrial origins should be avoided.
•	 The daily intake of fruit should be at least 
200 g. 
•	 The daily intake of vegetables should be at 
least 200 g. 
•	 Fish should be consumed 1–2 times a week 
as a minimum.
•	 Regular physical activity (at least 4–5 times 
a week) should be promoted: moderate phys-
ical activity of at least 150 minutes a week or 
intensive physical activity of at least 75 min-
utes a week. 
of 10 mg/day reduced the LDL-C concentration 
by 36.8% and 45.8%, respectively; at a  dose of 
20 mg/day – by 42% and 52.4%, respectively; and 
at a dose of 40 mg/day – by 47.8% and 55%, re-
spectively [47]. Statins cause a  moderate reduc-
tion in TG concentration. Atorvastatin at doses of 
10 mg/day, 20 mg/day and 40 mg/day has been 
found to decrease the TG level by 20%, 22.6% 
and 26.8%, respectively, and rosuvastatin used 
at the same doses – by 19.8%, 23.7% and 26.1%, 
respectively. The two statins play the most promi-
nent role due to the achievement of the therapeu-
tic target for LDL-C. However, their suitability for 
different patient groups varies. For example, ator-
vastatin is a safe statin in patients with CKD, and 
rosuvastatin at moderate doses is recommended 
in the elderly, as it has the best safety profile in 
this patient population [5]. 
The achievement of therapeutic targets for 
LDL-C depends on the baseline LDL-C concentra-
tion, strength and dose of the statin. However, 
a  doubling of the dose results in an additional 
decrease in the level of the lipid by only 6%. This 
relatively small additional lipid-lowering effect is 
believed to be attributable to an increased activ-
ity of PCSK9 during statin treatment (a feedback 
mechanism linked to a  decrease in LDL-C con-
centration and an increase in LDLRs on hepato-
cyte surface). The enzyme breaks down LDLRs in 
hepatocyte lysosomes. Consequently, after LDL-C 
particles are introduced into liver cells, they fail to 
return to the cell membrane to bind further lipo-
proteins [31, 32].
The main adverse reactions caused by statins 
include myotoxicity and new cases of diabetes 
(see Chapter 13) [5, 48]. The most common causes 
for discontinuing therapy are muscle symptoms. 
They include myalgia, ranging from mild to se-
vere in intensity, muscle stiffness and tenderness, 
cramps and weakening of muscular strength. They 
can be accompanied (or not) by a raised creatine 
kinase (CK) level. Factors predisposing to the de-
velopment of myopathy include age over 75 years, 
female gender, renal and hepatic dysfunction, hy-
pothyroidism, alcohol abuse, excessive physical 
exertion, genetic susceptibility, perioperative peri-
od and concurrent use of drugs inhibiting the me-
tabolism of statins such as clarithromycin, eryth-
romycin, azole antifungals, dilitiazem, verapamil, 
amiodarone, fibrates (particularly gemfibrozil), 
cyclosporin, clopidogrel, sulphonamides, red yeast 
rice [5, 32]. Statins may exhibit diabetogenic prop-
erties, however carbohydrate disorders/diabetes 
are not an indication to discontinue statin ther-
apy, as benefits in the form of CV risk reduction 
outweigh the side effects. In such cases, patient 
management comprises a  hypoglycaemic diet, 
loss of excessive body weight and prescription of 
antidiabetic drugs, if appropriate [32]. 
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Numerous RCTs have provided strong evi-
dence that statins are highly effective in prima-
ry and secondary prevention of CVD. The lower 
the LDL-C level achieved, the lower the risk of 
CV events. The correlation has been clearly cor-
roborated in a  meta-analysis of 26 randomized 
clinical trials investigating statins [49]. A  total 
of 21 studies (statins vs other interventions, 
mainly placebo) involving 126,526 patients have 
found that a 1 mmol/l (~40 mg/dl) decrease in 
LDL-C level results in a  significant reduction of 
CV events by 21%. The same study shows that 
intensive statin therapy compared to moder-
ate statin treatment (five studies in a  total of 
39,612 patients) is associated with a significant 
decrease in CV events by 28% per 1 mmol/l of 
LDL-C reduction (~40 mg/dl). Statin-based thera-
py reduces the incidence of stroke, fatal coronary 
events and overall mortality [49].
10.2. Fibrates
The mechanism of action, therapeutic indica-
tions, side effects and clinical outcomes associ-
ated with fibrates have recently been described 
in the Polish literature [46]. The action mech-
anism of fibrates depends on the activation of 
transcription factors called peroxisome prolifer-
ator-activated receptors α (PPARα) [38]. Fibrates 
are PPARα ligands and peroxisome proliferators. 
Through the activation of PPARα, the drugs in-
fluence the expression of key genes encoding 
proteins involved in lipid metabolism. A decrease 
in TG concentration is linked to the activation of 
oxidative enzymes which enhance the oxidation 
of fatty acids in the liver, ultimately reducing the 
synthesis of these lipids, and to an increased 
activity of lipoprotein lipase – an enzyme found 
on the vascular endothelium which triggers the 
hydrolysis of triglycerides, and thus their catabo-
lism. Fibrates induce an increase in the synthesis 
key PoInTS To reMeMber
•	 Statins are first-line drugs in the treatment 
of hypercholesterolaemia; they have the 
best documented efficacy of all lipid-lower-
ing medications in the primary and second-
ary prevention of CVD.
•	 In view of the need to achieve the therapeu-
tic target for LDL-C atorvastatin and rosu-
vastatin are currently the most commonly 
used statin drugs.
•	 During treatment, attention should be fo-
cused on side effects reported by patients, 
mostly muscle symptoms. If they occur, the 
recommended management should be fol-
lowed (see Chapter 13).
of Apo-Al and AII, i.e. two protein components of 
HDL-C [38, 46].
Fibrates reduce the concentration of TG by 25–
50% and increase the level of HDL-C by 10–25%. 
Currently, they are mainly used to treat hyper-
triglyceridaemia. In patients with severe hyper-
triglyceridaemia, pharmacotherapy should start 
with a fibrate in order to promptly reduce the se-
rum concentration of TG, which represents a risk 
factor for acute pancreatitis [32, 46]. The preferred 
fibrate is fenofibrate. According to the most recent 
(2016) ESC/EAS Guidelines for the management 
of dyslipidaemia, combination therapy (statin plus 
fenofibrate) should be considered in cases where 
the concentration of TG persists over 200 mg/dl 
(> 2.3 mmol/l) on statin treatment [6, 32].
Adverse reactions developing during fibrate 
treatment are rare and generally moderate in na-
ture. Myopathy and raised aminotransferase levels 
have been reported. Fibrates also elevate creati-
nine concentrations. Notably, they are eliminated 
via the kidneys in 60–90%, which restricts their 
use in patients with CKD. A rise in the concentra-
tion of homocysteine and cases of acute pancre-
atitis and thromboembolic disease have also been 
reported [46].
Large clinical trials on fenofibrate conducted in 
diabetic patients (FIELD – Fenofibrate Intervention 
and Event Lowering in Diabetes, and ACCORD – 
Action to Control Cardiovascular Risk in Diabetes) 
randomized for fenofibrate treatment have failed 
to demonstrate any effect on CV risk compared 
to placebo [50, 51]. However, a clinical benefit in 
reducing CV events has been noted in the sub-
groups of patients with atherogenic dyslipidae-
mia (elevated TG plus reduced HDL-C level). Un-
fortunately, there are no data from large RCTs on 
fibrate therapy given exclusively to patients with 
atherogenic dyslipidaemia. It should be noted that 
the U.S. Food and Drug Administration (FDA) has 
recently withdrawn its approval to combine nico-
tinic acid and fibrates with statins, as scientific ev-
idence does not support a reduction in the risk of 
CV events following a decrease in TG or increase in 
HDL-C levels due to the effect of the drugs.
key PoInTS To reMeMber
•	 The main indication for fibrate treatment is 
severe hypertriglyceridaemia. In such cases, 
a fibrate should be used as a first-line drug 
(see Chapter 10.9).
•	 The first-line drugs in patients with hyper-
triglyceridaemia are statins. A  fibrate may 
be considered as add-on to statin therapy in 
patients with persistent hypertriglyceridae-
mia (TG > 200 mg/dl or 2.3 mmol/l) despite 
using statins.
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10.3. Ezetimibe
Ezetimibe selectively inhibits the uptake of cho-
lesterol from the intestinal lumen into enterocytes 
by selectively blocking the sterol transport protein 
NPC1L1 (Niemann-Pick C1 protein) [52]. Due to 
a reduced absorption less cholesterol reaches the 
liver. As a result, the expression of LDL receptors 
on the surface of hepatocytes is elevated, leading 
to an increase in the hepatic uptake of endoge-
nous cholesterol contained in LDL lipoproteins. 
Ezetimibe therapy at a dose of 10 mg lowers 
the concentration of LDL-C in the range of 15–25% 
[53–55]. However, considerable inter-individual 
variation is seen, and can be attributed to dietary 
variability (a cholesterol-rich diet increases the lip-
id-lowering effect of the drug) and, probably, vari-
ation of genes encoding the NPC1L1 protein. As 
a result, some patients may respond to ezetimibe 
monotherapy better than others [56]. The drug re-
duces the concentration of TG by 1.7–9.4% [53, 
57] and brings a minimal (1.3–6.2%) increase in 
the HDL-C level [58]. 
Combination therapy with ezetimibe and a sta-
tin – due to their complementary activity – results 
in a  more pronounced decrease in the concen-
tration of LDL-C than that achieved with both 
drugs in monotherapy [59]. Ezetimibe added to 
a statin further reduces the LDL-C concentration 
by 15–20%. Published RCTs on ezetimibe have 
demonstrated a  high lipid-lowering efficacy and 
a beneficial safety profile of combination therapy 
in a group of patients with primary hypercholes-
terolaemia [60], kidney failure [61], type 2 diabe-
tes [62], metabolic syndrome [63], high CV risk 
[64] and acute coronary syndrome [44]. In all the 
studies, the optimal target concentration of LDL-C 
and a greater reduction in TC, non-HDL-C, TG and 
ApoB concentrations were achieved much more 
frequently in the patient group receiving combi-
nation treatment as compared to statin mono-
therapy. Furthermore, the results of the Improved 
Reduction of Outcomes: Vytorin Efficacy Interna-
tional Trial (IMPROVE-IT) study have shown that 
a LDL-C decrease achieved with ezetimibe signifi-
cantly lowers the incidence of CV events [44].
Ezetimibe is rapidly absorbed from the gastro-
intestinal tract, largely in the form of the pharma-
cologically active ezetimibe glucuronide. The bio-
availability of the drug is not significantly affected 
by simultaneous food intake. It is metabolized 
in the intestine and liver. It is neither an inducer 
nor an inhibitor of the cytochrome P450. As a re-
sult, it does not interact with drugs metabolized 
by this cytochrome. The concentration profile of 
ezetimibe is characterized by several peaks over 
a 24 hours period, which shows that the time of 
administration does not alter its activity [65]. The 
drug is excreted primarily in the faeces (78%), 
with a smaller portion excreted in the urine (11%). 
The pharmacokinetic parameters of ezetimibe in 
the elderly and in patients with renal failure or 
mild hepatic failure are not significantly altered 
[65]. However, the drug is contraindicated in pa-
tients with moderate and severe liver dysfunction. 
In contrast to drugs blocking the reuptake of bile 
acids, ezetimibe does not interfere with the ab-
sorption of fat-soluble vitamins, thyroid hormone, 
warfarin and β1 blockers. Ezetimibe inhibits the 
absorption of plant sterols and stanols, so their 
concomitant use is not indicated [32].
10.4. PCSK9 inhibitors
PCSK9 is a protein responsible for LDL-C metab-
olism associated with receptors for LDL-C, which 
are present in the blood and on the surface of liver 
cells [66]. The protein binds to LDLR on the hepato-
cyte surface and – together with LDL-C – it under-
goes endocytosis followed by the degradation of 
complexes in hepatic cell lysosomes. As a  result, 
the number of LDL receptors on the hepatocyte 
surface and in the blood decreases, leading to an 
increase in the LDL-C level [66]. The mechanism 
has been accidentally discovered in patients with 
very high LDL-C levels and diagnosed autoso-
mal dominant hypercholesterolaemia (a  gain-of-
function mutation in the PCSK9 protein) and in 
patients with very low LDL-C levels (< 20 mg/dl) 
with a  loss-of-function mutation following which 
the non-functional PCSK9 protein fails to bind to 
the LDLR, prompting the return of receptors back 
to the surface of hepatocytes and, ultimately, an 
effective reduction in LDL cholesterol [67]. The 
finding served as a  basis for initiating studies 
to investigate PCSK9 protein inhibitors (mainly 
monoclonal antibodies) which could be used as an 
adjunct to statins to achieve an effective reduction 
of LDL-C. A number of molecules using the mech-
anism outlined above are currently under study. 
The most advanced are studies on two subcuta-
neously administered monoclonal antibodies: ali-
rocumab (ODYSSEY) and evolocumab (PROFICIO). 
On 1 November 2016, Pfizer announced the dis-
continuation of studies on bococizumab (SPIRE 
trial). At present, results are awaited from studies 
evaluating the effect of the therapy on CV events 
(CVOT – cardiovascular outcomes trials). The first 
outcomes are expected in March 2017. 
key PoInTS To reMeMber
Ezetimibe in monotherapy should be consid-
ered in patients with statin intolerance and in 
the combination therapy when the target LDL-C 
concentration is not achieved at maximal toler-
ated statin doses. 
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So far, studies have been conducted in three 
groups of patients – at high CV risk, with famil-
ial hypercholesterolaemia and statin intolerance 
[66]. The studies have shown that the drugs ef-
fectively lower the LDL-C level (between 45% 
and 65% compared to placebo, depending on 
the patient group; and between 35% and 45% 
compared to ezetimibe), and thus help achieve 
the therapeutic targets in these groups in up to 
80–90% of study subjects. What is more, PCSK9 
inhibitors favourably affect other lipid profile 
parameters as well. They are effective at reduc-
ing the level of non-HDL-C (on average by 50% 
compared to placebo), ApoB (by about 50%), 
TG (15–20%) and Lp(a) (by about 25%), and in-
creasing the concentrations of HDL-C (5–10%) 
and ApoA1 (3–5%) [66, 68]. Based on random-
ized phase III trials evaluating the efficacy of 
treatment with PCSK9 inhibitors with respect to 
lipid profile parameters, the drugs (alirocumab 
and evolocumab) have been approved both by 
the U.S. FDA and the European Medicine Agen-
cy (EMA) in the following indications: in adults 
with primary hypercholesterolaemia (heterozy-
gous familial and non-familial types) or mixed 
dyslipidaemia, as an adjunct to diet: (1) in 
combination with a  statin or statin with other 
lipid-lowering therapies in patients unable to 
reach LDL-C goals with the maximum tolerated 
dose of a statin or (2) alone or in combination 
with other lipid-lowering drugs in patients who 
are statin-intolerant, or for whom a statin is con-
traindicated. In view of studies conducted in pa-
tients with homozygous FH (TAUSSIG and TESLA 
trials) evolocumab should also be considered in 
combination with other lipid-lowering drugs in 
adults and adolescents of at least 12 years of 
age diagnosed with homozygous FH [69]. The 
drugs are already reimbursed in a number of Eu-
ropean countries. In Poland, a decision regard-
ing their reimbursement will probably be made 
after the completion of two studies, FOURIER 
(evolocumab) (March 2017) and ODYSSEY 
OUTCOMES (alirocumab) (March 2018), which 
will provide answers to questions about the 
efficacy of treatment, effect on endpoints and 
safety of therapy. 
Studies completed to date have failed to iden-
tify any significant adverse reactions of PCSK9 
inhibitors in comparison to statins and/or eze-
timibe. Patients may occasionally exhibit symp-
toms (redness and tenderness) at the site of 
injection. In addition, typical symptoms accom-
panying therapy with monoclonal antibodies can 
be observed, including rhinitis and pharyngitis 
(< 5%), upper respiratory tract infections (about 
3%), back pain (about 3%), joint pain (about 2%), 
flu (about 2%) and nausea (about 2%). Despite ex-
tensive research and debates surrounding the is-
sue, no evidence has been found for an increased 
risk of muscle-related symptoms (myalgia and 
myopathy), an elevation in liver enzymes and cre-
atine kinase, new cases of diabetes or cognitive 
disorders [66, 68, 69].
10.5. Ion-exchange resins
Resins bind bile acids in the intestine, thus re-
ducing their concentration in the enterohepatic 
circulation. In this way, via a  feedback mecha-
nism, the conversion of cholesterol into bile ac-
ids is initiated in the liver. Reduced cholesterol 
content in hepatocytes increases the expression 
of the LDLR, which in turn lowers the LDL-C level 
in the serum [70]. In some patients, resins may 
intensify the formation of VLDL in the liver, re-
sulting in an increase in the serum concentration 
of TG. In addition, they lower the glucose level in 
diabetic patients. The addition of colesevelam to 
antidiabetic drugs significantly improves glycae-
mic control, however there are no data indicating 
that the treatment contributes to a decrease in 
CV risk [70]. 
Ion-exchange resins used at maximal doses 
(cholestyramine 24 g/day, colestipol 20 g/day or 
colesevalam 4.5 g/day) reduce the LDL-C level by 
18–25%. They have not been shown to affect the 
HDL-C level in a significant manner. In predisposed 
individuals (with diabetes or abdominal obesity), 
they may induce an increase in the concentration 
of TG. Cholestyramine treatment for the primary 
prevention in hypercholesterolaemia patients has 
been associated with a significant 19% reduction 
in CV events [71, 72]. 
Ion-exchange resins are not absorbed from 
the gastrointestinal tract and exhibit no systemic 
toxicity. However, they frequently cause adverse 
gastrointestinal effects (constipation, flatulence, 
nausea). Also, they reduce the absorption of 
fat-soluble vitamins. To avoid a  reduced absorp-
tion of other drugs, ion-exchange resins should be 
taken four hours before or 1 hour after the intake 
of other drugs. The best tolerated ion-exchange 
resin is colesevelam [73].
key PoInTS To reMeMber
•	 PCSK9 inhibitors may be considered in very 
high and high risk patients who, despite us-
ing maximal tolerated statin doses in combi-
nation with ezetimibe, still have high LDL-C 
levels, and in patients with statin intoler-
ance (see Chapters 12.3 and 13). 
•	 Studies conducted to date have not identi-
fied any significant adverse reactions asso-
ciated with treatment using drugs from this 
group. 
M. Banach, P. Jankowski, J. Jóźwiak, B. Cybulska, A. Windak, T. Guzik, A. Mamcarz, M. Broncel, T. Tomasik, et al.
20 Arch Med Sci 1, February / 2017
10.6. Nicotinic acid
Nicotinic acid (niacin) inhibits the process of 
lipolysis in the adipose tissue, decreasing the syn-
thesis of free fatty acids (FFA) and their influx to 
the liver. The process leads to a decrease in FFA 
supplied to the liver and, consequently, to a  re-
duced VLDL secretion. The decrease in VLDL syn-
thesis results in a reduced production of IDL and 
LDL. Furthermore, niacin directly inhibits hepatic 
diacylglycerol acyltransferase 2 (DGAT2) – a  key 
enzyme involved in triglyceride synthesis. Nicotin-
ic acid increases the synthesis of apoA1 in the liv-
er, leading to a rise in the concentration of HDL-C 
[74]. Nicotinic acid at a  dose of 2 g/day lowers 
the level of LDL-C by about 15–18%, TG by about 
20–40% and Lp(a) by 30%, and increases the con-
centration of HDL-C by 25% [74, 75].
Negative results obtained in two trials – Ath-
erothrombosis Intervention in Metabolic Syn-
drome With Low HDL/High Triglycerides: Impact 
on Global Health Outcomes (AIM-HIGH) [76] and 
the Heart Protection Study 2 – Treatment of HDL 
to Reduce the Incidence of Vascular Events (HPS2-
THRIVE) [77] – have considerably weakened the 
status of nicotinic acid in lipid-lowering thera-
py. In AIM-HIGH, adding extended-release niacin 
(1,500–2,000 mg/dl) to standard statin therapy 
has failed to induce an additional reduction in CV 
events despite a  recorded increase in the HDL-C 
level from  35 mg/dl (0.91 mmol/l) to 42 mg/dl 
(1.08 mmol/l), and reductions in TG from 164 mg/
dl (1.85 mmol/l) to 122 mg/dl (1.38 mmol/l) and 
in LDL-C – from 74 mg/dl (1.91 mmol/l) to 62 mg/
dl (1.60 mmol/l) [76]. Similarly, HPS2-THRIVE has 
not found any additional clinical benefit of a treat-
ment based on extended-release niacin with laro-
piprant (a  compound inhibiting the synthesis of 
prostaglandin D2 which is responsible for skin red-
ness and hot flushes) in combination with a statin 
[77]. Compared to statin monotherapy, the treat-
ment has been associated with significantly more 
infections, hyperglycaemia, new cases of diabetes, 
gastrointestinal and musculoskeletal symptoms, 
gastrointestinal bleeding and skin symptoms.
key PoInTS To reMeMber
•	 Monotherapy with an ion-exchange resin 
should be considered in patients who are 
intolerant of statins, and may be considered 
in the combination therapy when the ther-
apeutic target is not achieved at maximal 
tolerated statin doses. 
•	 Ion-exchange resins are safe to use during 
pregnancy and lactation. 
NOTE: No ion-exchange resin products are currently 
available in Poland.
10.7.  Drug combinations and future 
perspectives
Statins are highly effective at lowering the LDL-C 
level, however even treatment based on the most 
powerful statins – rosuvastatin (at 20–40 mg) 
and atorvastatin (at 40–80 mg) – is not able to 
fully eliminate CV risk [78]. Residual CV risk can 
be as high as 60–70%, so attempts have been 
made for many years to develop new drugs that 
will make it possible to reduce the risk level (see 
Chapter 8) [78]. 
From the practical viewpoint it seems that the 
central goal is to achieve a  reduction in residu-
al risk associated with LDL-C. In this indication, 
the most prominent medications nowadays are 
PCSK9 inhibitors and ezetimibe as an element of 
combined therapy with statins [79]. In this case, 
however, it is necessary to wait for the results of 
studies assessing the cardiovascular endpoints 
for PCSK9 inhibitors [79]. Another factor to bear 
in mind is FDA’s negative position on ezetimibe 
following the IMPROVE-IT trial, even though EMA 
and the most recent ESC/EAS guidelines for the 
management of dyslipidaemias recommend eze-
timibe for second-line therapy (in combination 
with statins) when the therapeutic target is not 
achieved at maximal tolerated statin dose or in 
patients intolerant of statins or with contraindica-
tions to these drugs [32, 80]. Another drug, which 
effectively reduces the concentration of LDL-C is 
bempedoic acid (ETC-1002), which acts through 
inhibiting ATP citrate lyase (ACL). In this case, 
however, results are awaited from phase III trials 
to determine whether the therapy is effective and 
safe [81]. 
It should be noted that some of the drugs which 
are commonly used in a number of countries are 
either rarely prescribed or unavailable in Poland. 
They include ion-exchange resins, nicotinic acid or 
some fibrates (bezafibrate). 
Other drug combinations have failed to demon-
strate efficacy in reducing residual risk associated 
with increased HDL-C levels (in trials evaluating 
nicotinic acid and CETP inhibitors – evacetrapib, 
dalcetrapib and torcetrapib; studies on anace-
trapib are still ongoing) [82]. At this point, a note 
key PoInTS To reMeMber
In 2013, EMA narrowed down the indications 
for an extended-release nicotinic acid product 
to the treatment of dyslipidaemias with high 
triglyceride levels and only as an alternative 
therapy. At the same time, niacin in combina-
tion with laropiprant was withdrawn from use.
NOTE: No nicotinic acid products are currently available 
in Poland.
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should be made of a new alternative drug which 
may potentially cause a  significant increase in 
HDL-C and ApoA1 concentrations and reduce 
the inflammatory process, particularly in diabetic 
patients [83]. The drug, called apabetalone (RVX-
208), is the first oral medication selectively induc-
ing the synthesis of ApoA-I [83]. However, further 
study results are needed to provide conclusive ev-
idence for its efficacy and safety. 
Debates are currently ongoing about the use 
of fibrates (mainly fenofibrate in Poland) for sec-
ond-line treatment of patients with diabetes, 
particularly in view of negative results obtained 
in the FIELD and ACCORD trials, and guidelines 
issued by the American College of Cardiology 
(ACC)/American Heart Association (AHA) in No-
vember 2013 [84, 85]. In the most recent ESC/
EAS guidelines (2016), however, the focus is on 
the importance of decreasing TG levels for reduc-
ing the risk of CV events. The guidelines recom-
mend treatment with fibrates (though not with 
gemfibrozil) in addition to statins in patients with 
mixed dyslipidaemia and with TG > 200 mg/dl 
(> 2.3 mmol/l) [32]. 
10.8.  Recommendations for dyslipidaemia 
treatment
Detailed recommendations for the treatment 
of dyslipidaemias are listed in Table XI, and rec-
ommendations for the intensity of lipid-lowering 
statin treatment in different CV risk groups are 
presented in Table XII. 
Table XI. Recommendations for dyslipidaemia treatment
recommendations Class  
of recommendation 
Level  
of evidence
Statins at maximal recommended or tolerated doses are indicated to 
achieve the therapeutic target
I A
If the target of therapy is not achieved, a combination of a statin with 
ezetimibe should be considered
IIa B
If the target of therapy is not achieved, a combination of a statin with an 
ion-exchange resin may be considered*
IIb C
In patients intolerant of statins, ezetimibe or an ion-exchange resin* or their 
combinations* should be considered
IIa C
PCSK9 inhibitors# may be considered in patients with a high and very 
high CV risk, with persisting high LDL-C concentrations despite treatment 
with maximal tolerated statin doses, in combination with ezetimibe or in 
patients who are intolerant of statins including:
•	 in patients with FH and CVD or other CV risk factors, family history of 
early-onset CVD or high Lp(a) levels
•	 in patients with FH without CVD and with at least one other CV risk 
factor who fail to achieve target LDL-C levels despite treatment with 
maximal tolerated statin doses, in combination with ezetimibe
•	 in patients after a CV event or with complicated diabetes and LDL-C 
levels persisting > 160 mg/dl (4.2 mmol/l) despite optimal lipid-lowering 
treatment
IIb C
Statin treatment may be considered for first-line management in high-risk 
patients with hypertriglyceridaemia to achieve a reduction in CV risk
IIb B
Adding fenofibrate to statin therapy may be considered in patients from 
high and very high risk groups with TG levels persisting > 200 mg/dl (2.3 
mmol/l) despite statin treatment
IIb C
*Not used in Poland; # evolocumab and alirocumab. 
key PoInTS To reMeMber
•	 Combined treatment offers possibilities for 
an effective reduction of residual CV risk, 
which is particularly important for high-risk 
patients.
•	 Studies conducted to date have demonstrat-
ed the highest efficacy of LDL-C-reducing 
drugs (ezetimibe and PCSK9 inhibitors) in sec-
ond-line therapy added to statin treatment.
•	 Other therapies associated with a reduction 
in HDL-C or TG levels have failed to show 
their efficacy in available clinical studies. Fur-
ther trials are needed to verify their benefits. 
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Table XII. Recommendations for the intensity of lipid-lowering statin treatment in different CV risk groups
risk group LDL-C – primary target non-HDL-C –  
secondary target
Type of therapy
Very high risk < 70 mg/dl (< 1.8 mmol/l)
in patients treated with 
a statin
< 100 mg/dl
(< 2.6 mmol/l)
Intensive lipid-lowering therapy
(%decrease in LDL-C by 50–60%)
•	 atorvastatin 40–80 mg/day
•	 rosuvastatin 20–40 mg/day
•	 simvastatin 40 mg + ezetimibe 10 mg/day
•	 atorvastatin 20 mg + ezetimibe 10 mg/day
•	 rosuvastatin  10 mg + ezetimibe 10 mg/day
or
Very intensive lipid-lowering therapy
(%decrease in LDL-C by over 60%)
•	 atorvastatin 40–80 mg + ezetimibe 10 mg/day
•	 rosuvastatin 20–40 mg + ezetimibe 10 mg/day
To be considered:
PCSK9 inhibitors – evolocumab 140 mg every 
other week subcutaneously or 420 mg once 
a month; 
alirocumab 75–150 mg every other week 
subcutaneously
When baseline LDL-C  
70–135 mg/dl  
(1.8–3.5 mmol/l)
Reduction by at least 50%
High risk < 100 mg/dl  
(< 2.6 mmol/l) in patients 
treated with a statin
< 130 mg/dl
(< 3.3 mmol/l)
Intensive lipid-lowering therapy
(%decrease in LDL-C by at least 50%)
•	 atorvastatin 20–40 mg/day
•	 rosuvastatin 10–20 mg/day
•	 simvastatin 20–40 mg + ezetimibe 10 mg/day
•	 atorvastatin 10–20 mg + ezetimibe 10 mg/day
•	 rosuvastatin 5–10 mg + ezetimibe 10 mg/day
When baseline LDL-C > 190 mg/dl (> 4.9 mmol/l)
Very intensive lipid-lowering therapy
(%decrease in LDL-C by over 60%)
•	 atorvastatin 40 mg + ezetimibe 10 mg/day
•	 rosuvastatin 20 mg + ezetimibe 10 mg/day
To be considered:
PCSK9 inhibitors – evolocumab 140 mg every 
other week subcutaneously or 420 mg once 
a month; 
alirocumab 75 mg every other week 
subcutaneously or 150 mg every other week 
subcutaneously
When baseline LDL-C  
100–190 mg/dl  
(2.6–4.9 mmol/l)
Reduction by at least 50%
Moderate 
and low risk
< 115 mg/dl
(< 3 mmol/l)
– •	 simvastatin 20–40 mg/day
•	 atorvastatin 10–20 mg/day
•	 rosuvastatin 5–10 mg/day
key PoInTS To reMeMber
•	 Statins are indicated at maximal recommended (depending on the patient group and CV risk) or 
tolerated doses to achieve the therapeutic target.
•	 If the target of therapy is not achieved, a combination of a statin with ezetimibe should always 
be considered. 
•	 Ezetimibe should be considered in patients intolerant of statins or with contraindications to these 
drugs. 
•	 PCSK9 inhibitors may be considered in very high and high risk patients who, despite treatment 
with maximal tolerated statin doses in combination with ezetimibe, still have high LDL-C levels, 
and in patients with statin intolerance.
•	 Fenofibrate may be used in combination with a statin in patients from high and very high risk 
groups with TG levels persisting > 200 mg/dl (> 2.3 mmol/l) despite statin treatment.
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10.9. Severe hypertriglyceridaemia
Severe hypertriglyceridaemia (HTG) is charac-
terized by an elevated serum level of triglycerides 
to > 880 mg/dl (> 10 mmol/l) which is not accom-
panied by an increase in LDL-C concentration [32]. 
The condition is associated with an increased risk 
of acute pancreatitis (AP). HTG can be divided into 
the familial type and chylomicronaemia syndrome. 
A useful method for the differentiation of severe 
HTG is cold flotation test which is performed to 
detect chylomicrons. Following centrifugation, se-
rum samples are placed in the refrigerator at 4°C 
for 16 hours. A layer of fat identified on the sur-
face of the serum after the elapse of that time is 
indicative of the presence of chylomicrons [32].
Familial hypertriglyceridaemia 
The condition is passed on in an autosomal 
dominant pattern. It typically manifests itself in 
adulthood in response to triggers including un-
balanced high-fat diet, high carbohydrate con-
sumption (> 60% of total caloric intake), alcohol 
consumption and obesity. It should always be 
verified whether the patient takes medications 
increasing TG levels (Table XIII). In many cases, 
a low-lipid diet and elimination of alcohol make it 
possible to reduce the TG level to reference values 
(< 150 mg/dl (< 1.7 mmol/l)) over a short period 
of about 2 weeks. Effective treatment is based on 
fibrates in monotherapy or in combination with 
omega-3 fatty acids (2–4 g/day) [6, 32].
Chylomicronaemia syndrome
Very high TG concentrations can also be a result 
of deficiency of lipoprotein lipase or lipase cofactor 
ApoC-II – a disorder inherited in an autosomal re-
cessive pattern. The condition is called chylomicro-
naemia syndrome [86, 87]. In its homozygous form, 
which affects 1/1,000,000 people, symptoms pres-
ent as early as in infancy and include skin xanthom-
as, lipemia retinalis, growth disturbances, recurrent 
acute pancreatitis, hepatosplenomegaly, mental 
disorders. In heterozygous individuals, the disease 
develops later in life. The treatment comprises 
a diet with a very low intake of fat in every form, 
Table XIII. Secondary causes of hypertriglyceridaemia
Causes of HTG
Genetic predisposition
Obesity
Type 2 diabetes
Alcohol use
Diet rich in simple sugars
Kidney disease
Hypothyroidism
Pregnancy (TG level rises two-fold in the third 
trimester of pregnancy)
Paraproteinaemia I autoimmune diseases: systemic 
lupus erythematosus
Drugs: glucocorticosteroids, oral oestrogens, non-
cardioselective β blockers, thiazides, 
retinoids, tamoxifen, protease inhibitors used for 
treating HIV infection, cyclophosphamide, cyclosporin, 
L-asparaginase, phenothiazines, second-generation 
antipsychotics (clozapine, olanzapine)
Table XIV. Types of hypertriglyceridaemia and management recommendations
Mild to moderate Severe
TG concentration 150–880 mg/dl (1.7–10 mmol/l) > 880 mg/dl (> 10 mmol/l)
Central target of therapy Reduction of CV risk Reduction of AP risk
Primary target of therapy Target LDL-C Reduction of TG
Secondary target of 
therapy
Target non-HDL-C level Target LDL-C and non-HDL-C levels if the 
risk of AP is reduced
Non-pharmacological 
treatment
Lifestyle modification, body weight loss, 
regular physical activity, low-fat diet, 
cessation of alcohol intake
Lifestyle modification, body weight 
loss, total cessation of alcohol intake, 
restrictive low-fat diet, AP treatment in 
accordance with applicable guidelines
Drugs Statins – first-line drugs (atorvastatin, 
rosuvastatin); to consider: combined 
therapy with a fibrate (when TG 
concentration persists > 200 mg/dl  
(> 2.3 mmol//l)), omega-3 fatty acids (2–4 g/
day) – at maximal tolerated statin dose
Fibrate in combination with omega-3 
fatty acids (2–4 g/day)
Alternative treatment: nicotinic acid*
Genetic tests Polygenic in form 
No indications for genetic tests
Very likely monogenic in form, 
genetic tests indicated in children 
and adolescents, cold flotation test 
recommended to detect chylomicrons
AP – acute pancreatitis, *unavailable in Poland. 
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both of animal and plant origin. Often, supplement-
ing the diet with medium-chain fatty acids, which 
do not form chylomicrons after absorption, is nec-
essary. In this form, fibrates are less effective than 
in familial hypertriglyceridaemia, and the prognosis 
is worse. In patients with chylomicronaemia syn-
drome treatment is considered effective if the TG 
level is < 500 mg/dl (< 5.6 mmol/l). HTG types and 
patient management recommendations are shown 
in Table XIV [32, 86, 87].
Prevention of AP in hypertriglyceridaemia
Hypertriglyceridaemia is the underlying cause 
of about 10% of all AP cases. It needs to be 
stressed that AP does not have to be secondary 
to severe hypertriglyceridaemia (TG > 880 mg/dl 
(> 10 mmol/l)), but it may also develop at TG con-
centrations of 400–880 mg/dl (4.5–10 mmol/l). 
A prominent rise in the risk of AP is observed in 
response to an additional factor increasing VLDL 
production, such as alcohol [86, 87].
11.  LDL-C APHereSIS – MeTHoDoLoGy  
AnD InDICATIonS
LDL-apheresis is a  procedure to remove LDL 
from the blood serum rapidly. Although the meth-
od involves high costs and is time-consuming, it 
is recognized as an important adjuvant therapy 
for homozygous familial hypercholesterolaemia 
(hoFH) [88–91]. Clinical observations show that 
long-term LDL-apheresis in patients with severe 
hoFH contributes to the regression and stabiliza-
tion of atheromatous plaques, improves CV out-
come and reduces skin and tendon xanthomas 
[92]. A  single procedure makes it possible to de-
crease LDL-C by 55–70% [93]. LDL-apheresis proce-
dures should be repeated on a weekly to biweek-
ly basis. Blood collected from the patient is first 
separated in a separator into morphotic elements 
and plasma which then passes into a set of LDL-C 
key PoInTS To reMeMber
Practical management guidelines: 
1. High TG level > 400 mg/dl (> 4.5 mmol/l) and 
symptoms of AP – hospitalization.
2.  High TG level > 400 mg/dl (> 4.5 mmol/l) with 
no symptoms – close monitoring on an out-
patient basis until a decrease in the TG level: 
(a) diet with restricted calorie and fat intake 
(10–15%), (b) complete cessation of alcohol 
consumption, (c) treatment: fenofibrate in 
monotherapy or in combination with ome-
ga-3 acids, (d) in patients with diabetes – in-
troduction of intensive insulin therapy. In the 
majority of cases a  decrease in TG is seen 
within 2–5 days.
separation filters. Following filtration, plasma to-
gether with cellular elements is transfused back 
to the patient. The procedure takes approximately 
4 hours. In addition to LDL-C, apheresis also re-
moves VLDL, fibrinogen, Lp(a), α2-macroglobulin 
and coagulation factors from blood plasma [91]. 
The time of initiation of therapy depends on the 
patient’s response to lipid lowering drugs and the 
presence of coronary heart disease (the patient’s 
risk level) [91–93]. The earlier the treatment is ini-
tiated, the better the patient’s outcome. Whenever 
possible, LDL-apheresis should optimally be initiat-
ed in patients with hoFH at the age of 5 years and, 
at the latest, at the age of 8 years [93]. The method 
can be safely used during pregnancy [88, 91].
The most serious adverse reactions associated 
with LDL-apheresis include hypotonia, abdominal 
pain, nausea, vomiting, dizziness and headaches, 
hypocalcaemia, iron deficiency anaemia, allergic 
reactions, haemolysis and thrombocytopenia. On 
account of the risk of hypotonia in patients treated 
for arterial hypertension, a dose of their hypotensive 
drugs should be omitted on the day of the procedure. 
In patients treated with dextran sulphate or hae-
moperfusion, taking an angiotensin-converting-en-
zyme inhibitor carries the risk of severe hypotonia 
and is thus contraindicated [94]. Patients requiring 
ongoing oral anticoagulation therapy with warfarin 
or acenocoumarol should interrupt their treatment 
at least 4 days before the scheduled LDL-apheresis 
procedure, and should start taking low molecular 
weight heparin. Such patients also require monitor-
ing of their complete blood count (CBC) and iron pro-
file, and supplementation, as required. Antiplatelet 
therapy should not be interrupted.
LDL-apheresis procedures should only be per-
formed in highly specialized medical centres. 
When the Guidelines were drafted, there were 
three such centres operating in Poland, based in 
Gdansk, Poznan and Szczecin.
key PoInTS To reMeMber
•	 LDL-apheresis should be considered in the 
treatment of patients with hoFH as an ad-
junct therapy [88–94]. 
•	 In exceptional situations, LDL-apheresis is 
used in patients with the heterozygous form 
of familial hypercholesterolemia (heFH), 
when further progression of clinically symp-
tomatic atherosclerosis is observed despite 
treatment with maximal statin doses. 
•	 LDL-apheresis is recommended when de-
spite a diet and pharmacotherapy at maxi-
mal tolerated doses the LDL-C level persists 
for 6 months ≥ 300 mg/dl (≥ 7.7 mmol/l) or 
≥ 200 mg/dl (≥ 5.2 mmol/l) in patients with 
documented coronary heart disease. 
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12.  TreATMenT oF LIPID DISorDerS  
In SeLeCTeD PoPuLATIonS
12.1. Children and adolescents
There are no reliable data assessing the effica-
cy and safety of long-term treatment of dyslipi-
daemias in children and adolescents. The general-
ly held view is that treatment should be initiated 
during childhood [95]. The deferral of appropriate 
therapy until adulthood can lead to cardiovascular 
diseases at a young age. Therapeutic recommen-
dations for children and adolescents are largely 
extrapolated from studies on FH and studies con-
ducted in adults.
The target in the treatment of dyslipidaemia in 
children and adolescents is the LDL-C level < 130 mg/ 
dl (< 3.4 mmol/l, under the 95th percentile), and in 
children with diabetes < 100 mg/dl (< 2.6 mmol/l) – 
or an LDL-C reduction by at least 50% [96, 97]. 
The treatment of dyslipidaemia in children and 
adolescents consists of health education, lifestyle 
modifications and pharmacotherapy. Education 
should involve all members of the patient’s family. 
The scope of information and the way it is com-
municated should take into account the child’s 
age and the efficiency of communicating with car-
ers. It is necessary to allow an appropriate amount 
of time for providing information. If required, the 
task should take several appointments. Informa-
tion provided to patients and their families should 
include causes and effects of lipid disorders, risk 
factors for cardiovascular diseases, and rules 
and importance of therapy. Individual counsel-
ling should be ensured, and the opinions, fears 
and doubts of young patients and their families 
should be properly addressed. Patient manage-
ment decisions should also be made collectively. 
It is reasonable to minimize the risk of contradic-
tory information being provided, particularly by 
physicians and nurses within the same medical 
practice, or by medical professionals in a special-
ist healthcare unit. Successful education is facili-
tated by previously established good therapeutic 
relations and knowledge of psychosocial factors 
which either support changes in behaviour (e.g. 
positive emotions, high social status) or hinder 
them (stress, family tensions, social deprivation) 
[6, 98]. Lifestyle changes include introduction and 
reinforcement of good eating habits, focus on 
more physical activity, achievement of healthy 
body weight, prevention of passive smoking and, 
in adolescents, elimination of active smoking and 
alcohol consumption. Lifestyle measures should 
be introduced in all children over the age of 
2 years, when their LDL-C level is > 130 mg/dl 
(3.4 mmol/l) and/or the TG concentration is elevat-
ed (children under 10 years of age with TG ≥ 100 
mg/dl (≥ 1.1 mmol/l); children aged 10–19 years 
with TG levels ≥ 130 mg/dl (≥ 1.5 mmol/l)) [99]. 
Dietary treatment should be initiated in all chil-
dren with dyslipidaemia over the age of 2 years. 
Earlier dietary modifications should be prescribed 
by an experienced physician in a specialist health-
care unit, in cooperation with a  dietician. They 
require close monitoring of the child’s develop-
ment [99, 100]. If the effects of dietary treatment 
undertaken in the family physician’s practice are 
unsatisfactory, the patient and their family should 
be referred for a dietary consultation (not included 
in health services provided by the National Health 
Fund) or to a  specialist healthcare unit (outpa-
tient clinic for cardiac or metabolic diseases), 
which provides such services. An elevated LDL-C 
level is an indication for decreasing the energy 
intake from fats to 30% (including < 7% of satu-
rated fats), substituting saturated for unsaturated 
fats, and reducing the daily cholesterol intake to 
< 200 mg [96]. It is recommended to increase the 
intake of dietary fibre (to about 10 g at the age of 
5 years, 15 g at the age of 10 year and 20 g at the 
age of 15 years), sea fish, vegetables, fruit, nuts and 
seeds; opt for low-fat milk and enrich the diet with 
plant sterols and stanols (to 20 g/day) [97, 100]. An 
increased TG level is an indication to cut down on 
simple sugars, increase the intake of dietary fibre 
and complex sugars, and reduce body weight.
Parents should be encouraged to impose a ban 
on watching television in children under the age of 
2 years. In older children, time spent in front of TV/
computer should be reduced to 2 hours a day, and 
they should be encouraged to engage in physical 
activity for up to 90 minutes daily [97, 99, 101].
Table XV. Initiation of pharmacotherapy in children and adolescents, risk factors and lipid levels [96–99]
Patient characteristics Lipid parameters and their concentrations
Without cardiovascular risk factors LDL-C ≥ 190 mg/dl (≥ 4.9 mmol/l)
With one high* risk factor and two intermediate** risk 
factors, family history of early-onset cardiovascular disease
LDL-C ≥ 160 mg/dl (≥ 4.2 mmol/l) 
With diabetes LDL-C ≥ 130 mg/dl (≥ 2.6 mmol/l)
With or without risk factors TG ≥ 200 mg/dl (≥ 2.2 mmol/l)
*High risk factors: hypertension requiring pharmacotherapy, end-stage renal disease, BMI > 97 percentile. **Intermediate risk factors: 
arterial hypertension without pharmacotherapy, HDL < 1.0 mmol/l (< 40 mg/dl), BMI 95–97 percentile, chronic inflammatory disease 
(rheumatoid arthritis, systemic lupus erythematosus), nephrotic syndrome.
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Pharmacotherapy should be introduced 6 months 
after the lifestyle modification, if the therapeutic 
goals have not been achieved. Its long-term effi-
cacy and safety have not been determined. With 
regard to statins, the prevailing view is that they 
are well tolerated [102]. The lipid parameter lev-
els at which pharmacotherapy is recommended in 
children and adolescents ≥ 10 years are shown in 
Table XV.
Statin therapy can be prescribed by family phy-
sicians to children > 10 years of age (except for 
children with FH, where the Polish Lipid Expert 
Forum recommends statins in children > 8 years 
of age, and in children with the homozygous form 
< 8 years of age at LDL-C concentrations > 500 mg/dl 
(12.9 mmol/l)) [96]. The treatment should be based 
on results of lipid profiling tests performed twice 
in the period between 2 weeks and 3 months in 
the fasting state, and evaluation of CV risk factors. 
The therapy is started with the lowest available 
dose which is taken once daily, in the evening [96, 
97]. The dose should be increased slowly, depend-
ing on the therapeutic outcome achieved, while 
monitoring potential adverse effects. Before initi-
ating treatment, the activity of aminotransferases 
and creatine kinase should be determined. The 
level of aminotransferases should be evaluat-
ed again approximately 6 weeks after introduc-
ing statin treatment [95–97]. Ezetimibe therapy 
should be started under the supervision of a phy-
Table XVI. Drugs used in the treatment of dyslipidaemias in children and adolscents [96, 100]
Drug(s) Doses Possible side effects  
(selection)
Contraindications in children
Starting Maximal
Statins: Liver damage, myalgia, 
myopathy, rhabdomyolysis, 
gastrointestinal disorders, 
fatigue, insomnia, 
headaches, skin lesions, 
peripheral neuropathy, 
lupus like syndrome
Drug hypersensitivity reactions,
statin-associated myopathy, 
active liver disease, high 
aminotransferase activity or 
threefold exceeding of the normal 
range during statin treatment, 
kidney failure, severe infections, 
serious injuries and surgical 
procedures, severe electrolytic, 
metabolic and hormonal disorders, 
uncontrolled epilepsy
Simvastatin 5 mg 40 mg
Atorvastatin 5 mg 40 mg
Rosuvastatin 5 mg 20 mg
Pravastatin 5 mg 20 mg  
until 13 years
40 mg  
until 18 years
Resins binding bile acids:  Headaches, flatulence, 
constipation, vomiting, 
diarrhoea, dyspepsia, 
abdominal pain, abnormal 
stools, nausea, abdominal 
distension
Drug hypersensitivity reactions, 
intestinal or biliary obstruction
Colesevelam** 1.25 g 3.75 g*
Drug inhibiting cholesterol absorption: Myalgia, myopathy and 
rhabdomyolysis, fatigue, 
headaches, abdominal pain, 
diarrhoea, flatulence with 
passing gas, dyspepsia, 
GERD, nausea, elevated 
aminotransferase level
Drug hypersensitivity reactions, 
liver dysfunction, unexplained high 
level of aminotransferases  Ezetimibe 10 mg 10 mg*
*No precise recommendations regarding dosage in children; **Unavailable in Poland. 
key PoInTS To reMeMber
•	 Dyslipidaemia treatment should be initiated during childhood, as the deferral of therapy until 
adulthood can lead to cardiovascular diseases at a young age. 
•	 The target of dyslipidaemia treatment in children and adolescents is the LDL-C level < 130 mg/dl 
(< 3.4 mmol/l), and in children with diabetes < 100 mg/dl (< 2.6 mmol/l) or a reduction in the LDL-C 
level by at least 50%.
•	 Health education should be provided both to the patient and to all members of the patient’s family. 
Lifestyle recommendations in children and adolescents are similar to those applicable to adults; 
dietary treatment in the family physician’s practice should not be undertaken in children before the 
age of 2 years.
•	 Pharmacotherapy should be initiated 6 months after introducing lifestyle modifications if no ther-
apeutic effect has been achieved; statins may be initiated in children > 10 years of age (> 8 years 
of age in children with heterozygous familial hypercholesterolaemia), starting with the lowest 
available dose. 
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sician at a specialist healthcare unit. The safety of 
use and efficacy of the drug in patients under 17 
years of age have not been assessed. Moreover, 
there are no precise recommendations regarding 
the dosage regimen. The situation is similar for 
colesevelam, which has been approved for the 
treatment of adults (unavailable in Poland) [99, 
100]. The doses of lipid-lowering drugs in children 
together with side effects and contraindications 
are listed in Table XVI.
12.2. The elderly
Cholesterol is a significant risk factor for coronary 
heart disease. The correlation is slightly less pro-
nounced in elderly patients. A 1 mmol (38.7 mg/dl) 
reduction in the TC level is associated with a de-
crease in CV mortality in patients aged 40–49 years 
by about 50% (hazard ratio (HR) – 0.44), and in pa-
tients aged 80–89 by 15% (HR – 0.85) [25, 103]. 
The primary method of preventing CVD in el-
derly patients is the promotion of healthy lifestyle. 
So far, there have not been any studies assessing 
the efficacy and safety of lipid-lowering therapy in 
primary prevention in the elderly population [103]. 
A post-hoc analysis of the Justification for the Use of 
Statins in Primary Prevention: An Intervention Trial 
Evaluating Rosuvastatin (JUPITER) study with rosu-
vastatin in a subgroup of elderly and younger pa- 
tients (under 70 years of age) has shown that the 
degree of reduction of the combined endpoint is 
independent of age [104]. To prevent one CV event 
over a period of 4 years, statin treatment should 
be provided to 24 elderly patients and 36 pa- 
tients at a younger age [104]. The continuation of 
lipid-lowering treatment in patients who started 
therapy under 75 years of age is believed to be 
a  rational option. According to the most recent 
(2016) ESC/EAS guidelines for the management 
of dyslipidaemias, lipid-lowering treatment in the 
elderly population without coronary heart disease 
should be considered in patients who, aside from 
age, have at least one other risk factor: smoking, 
arterial hypertension, diabetes or dyslipidaemia 
[32]. In secondary prevention, statin treatment is 
recommended to elderly patients diagnosed with 
CVD according to the same therapeutic principles 
as in younger patients [32, 105, 106].
Elderly age is a  factor which significantly af-
fects the pharmacokinetics of drugs, chiefly at the 
stage of distribution (increase in adipose tissue 
mass and α1-acid glycoprotein, reduced water 
content and albumin concentration) and elimina-
tion (impaired renal function, slower hepatic me-
tabolism) [32, 107–110]. Treatment applied to this 
patient group is further complicated by multiple 
morbidities, need to use polypharmacotherapy 
and non-compliance with medical advice. Elder-
ly age is an independent factor for an increased 
risk of statin intolerance [5]. Therefore, the Inter-
national Lipid Expert Panel (ILEP) recommends 
statins with hydrophilic properties (rosuvastatin, 
pravastatin) for the treatment of elderly patients, 
as they are associated with a higher level of thera-
peutic safety [5]. Statin treatment should begin at 
small doses which should be gradually increased 
until the achievement of the target LDL-C concen-
tration [32]. A temporary discontinuation of statin 
therapy should be considered in elderly patients 
in situations increasing the risk of statin intoler-
ance such as hypothyroidism, severe acute infec-
tion, extensive surgery and malnutrition, bearing 
in mind that the interruption of therapy increases 
the risk of all-cause and CV mortality [5]. 
12.3. Familial hypercholesterolaemia (FH)
Familial hypercholesterolaemia occurs most 
commonly in the heterozygous form (HeFH). Ho-
mozygous FH is very rare: based on recent epi-
demiological data, its incidence is estimated at 
1 : 300,000. On the basis of a  meta-analysis of 
six large observational studies, in accordance with 
the criteria issued by the Dutch Lipids Clinics Net-
work, heFH in Poland has been diagnosed in ap-
proximately one per 250 individuals aged 20–79 
years [24], which corresponds roughly to a  total 
of 122,590 FH patients in the Polish population 
(based on Central Statistical Office data on the 
population of Poland, 2014). The causes, diagnos-
tic criteria and management strategies in FH have 
lately been addressed in a number of publications 
by experts from scientific societies and other ex-
pert groups [111–115].
The most common cause of FH is a mutation 
in the LDL receptor gene. A less common cause is 
a mutation in the LDL protein (ApoB) gene, and the 
least common (1–3%) – a mutation in the gene re-
sponsible for the synthesis of the enzyme PCSK9. 
key PoInTS To reMeMber
•	 Statin treatment in elderly patients with CVD 
should follow the same rules as in younger 
patients.
•	 Due to multiple morbidities, risk of interac-
tions and modified drug pharmacokinetics, it 
is recommended to initiate statin treatment 
at low doses and then carefully increase the 
dose until the target LDL-C is achieved (the 
same as in younger individuals under 65 
years of age).
•	 In primary prevention, statin treatment 
should be considered when, in addition to 
age, there is at least one other risk factor 
such as arterial hypertension, smoking, dia-
betes or dyslipidaemia.
M. Banach, P. Jankowski, J. Jóźwiak, B. Cybulska, A. Windak, T. Guzik, A. Mamcarz, M. Broncel, T. Tomasik, et al.
28 Arch Med Sci 1, February / 2017
The PCSK9 mutation, of the gain-of-function type, 
is responsible for the breakdown of LDLRs in he-
patocyte lysosomes. Consequently, they do not 
return to the cell surface for new LDL particles, re-
sulting in a significant increase in the LDL-C level. 
Genetic diagnosis requires DNA testing. However, 
it is not always possible to identify the mutation 
responsible for the disease. Patients with HeFH in-
herit the condition from one parent. If they have 
a defect in the LDLR, only a half of all LDL receptors 
function normally.
The disease is a  factor strongly predisposing 
to premature atherosclerosis. The risk of coronary 
disease is high: CV mortality in FH patients aged 
between 20 and 39 years can be up to 100 times 
higher than in the same disease-free population [2, 
116]. The clinical diagnosis takes into account high 
LDL-C levels in the patient and their first-degree 
relatives (parents, siblings, children), premature 
CVD in the patient and their first-degree relatives, 
tendon xanthomas (not always), and premature 
arcus senilis (Table XVII). Genetic testing, despite 
determining the diagnosis, does not influence the 
treatment. The experiences of European health-
care centres indicate that genetic tests corroborat-
ing the diagnosis are performed in less than 25% 
of all patients. This is motivated by the fact that 
determining the LDL-C concentration in the closest 
family members in combination with detailed his-
tory and physical examination not only substan-
tiate the diagnosis but in fact make it possible to 
establish the clinical diagnosis of HeFH in such in-
dividuals and undertake their treatment.
HeFH patients should receive intensive statin 
treatment – atorvastatin (80 mg/day) or rosuvas-
tatin (40 mg/day). If the target LDL-C concentration 
< 100 mg/dl (< 2.6 mmol/l) or < 70 mg/dl (< 1.8 
mmol/l) in patients with CVD fails to be achieved 
with an optimal maximally tolerated statin dose, 
ezetimibe should be added [32]. If the two-drug 
therapy does not lead to the achievement of tar-
get LDL-C values, the addition of PCSK9 inhibitors 
(evolocumab or alirocumab) should be considered 
(see Chapter 10.8). In children, the main focus is on 
dietary treatment. A statin may be considered in 
children older than 8 years (see Chapter 12.1) [96]. 
key PoInTS To reMeMber
•	 Heterozygous familial hypercholesterolae-
mia is a much more common condition than 
previously thought: the incidence in the Pol-
ish population is one case per 250 adults 
(corresponding to almost 125,000 people 
aged over 20 years).
•	 Cascade family screening should be per-
formed in all members of the patient’s family.
•	 HeFH is a factor, which very significantly in-
creases the risk of premature coronary dis-
ease.
•	 HeFH patients receive intensive statin treat-
ment – atorvastatin (40–80 mg/day) or rosu-
vastatin (20–40 mg/day).
•	 If the target LDL-C concentration (< 100 mg/
dl (< 2.6 mmol/l) or < 70 mg/dl (< 1.8 mmol/l) 
in patients diagnosed with CVD) is not 
achieved, the addition of ezetimibe should be 
considered; if the target still is not achieved 
or the patient is intolerant of statins, the ad-
dition of PCSK9 inhibitors (evolocumab or 
alirocumab) may be considered.
Table XVII. Diagnostic criteria for heterozygous familial hypercholesterolaemia (HeFH) based on the Dutch Lipid 
Clinic Network [3, 32]
Criteria Score [points]
Family history First-degree relative with premature CVD and/or with LDL-C > 95th centile 
(190 mg/dl – 5.0 mmol/l)
1
First-degree relative with tendon xanthomas and/or < 18 years of age  
with LDL-C > 95th centile (155 mg/dl – 4.0 mmol/l)
2
Individual medical 
history
Premature CVD (under 55 years of age in men and under 60 years of age  
in women)
2
Premature cerebral or peripheral artery disease 1
Physical 
examination
Tendon xanthomas 6
Arcus senilis under 45 years of age 4
LDL-C ≥ 330 mg/dl (≥ 8.5 mmol/l) 8
250–329 mg/dl (6.5–8.4 mmol/l) 5
190–249 mg/dl (5.0–6.4 mmol/l) 3
155–189 mg/dl (4.0–4.9 mmol/l) 1
DNA testing Mutation in LDLR, ApoB or PCSK9 genes 8
*Interpretation: > 8 points – definite HeFH, 6–8 points – probable HeFH, 3–5 points – possible HeFH. 
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12.4. Metabolic syndrome and diabetes
Metabolic syndrome (MetS) refers to the coex-
istence of at least three out of five factors listed 
below:
•	 waist circumference ≥ 80 cm in women and 
≥ 94 cm in men,
•	 TG concentration ≥ 150 mg/dl (≥ 1.7 mmol/l) 
or dyslipidaemia treatment,
•	 HDL-C concentration < 50 mg/dl (< 1.3 mmol/l) 
in women and < 40 mg/dl (< 1.0 mmol/l) in 
men or dyslipidaemia treatment,
•	 systolic arterial pressure ≥ 130 mm Hg and/or 
diastolic arterial pressure ≥ 85 mm Hg or hypo-
tensive therapy,
•	 fasting glucose level ≥ 100 mg/dl (≥ 5.6 mmol/l) 
or hypoglycaemic treatment [6, 32]. 
MetS patients are affected by the so-called 
atherogenic dyslipidaemia, which involves mainly 
hypertriglyceridaemia and low HDL-C concentra-
tion; the concentration of LDL-C can be elevated 
or in the normal range, dominated by the frac-
tion of sdLDL, which additionally increases the 
risk level in these patients [32]. The increase in 
CV risk in affected patients is much higher than 
the simple sum of risks associated with individual 
constituents of the syndrome It is associated with 
a three- to sixfold increase in the risk of diabetes 
and a nearly twofold increase in all-cause mortali-
ty and CV events [6, 32]. 
Diabetes is a strong independent factor for CV 
risk. Since diabetes is associated with a three- to 
fivefold risk increase, it is considered to be equiv-
alent to CVD (particularly diabetes with complica-
tions and (an)other risk factor(s)) [6]. All diabetic 
patients are classified as being at high or very 
high risk. Consequently, they should receive in-
tensive treatment comprising both non-pharma-
cological interventions and pharmacotherapy [6, 
32]. In patients with type 2 diabetes without other 
risk factors and organ complications, the goal of 
lipid-lowering therapy is lowering the LDL-C lev-
el below 100 mg/dl (2.5 mmol/l). The secondary 
target of therapy in this group is to reduce the 
concentration of non-HDL-C below 130 mg/dl 
(3.3 mmol/l) [32]. Patients with diagnosed CVD or 
severe CKD, and patients over 40 years of age with 
coexisting risk factors and organ damage, should 
be considered as being at very high risk, and mea-
sures should be undertaken with a view to lower-
ing the LDL-C level below 70 mg/dl (1.8 mmol/l) 
or, as a minimum, to half of their baseline value 
[32]. The secondary target of therapy in this pa-
tient group is to reduce the concentration of non-
HDL-C below 100 mg/dl (2.6 mmol/l) [32]. Since 
the Heart Protection Study (HPS), scientific trials 
have demonstrated that all patients with type 2 
diabetes benefit significantly from statin treat-
ment (with/without the addition of ezetimibe), 
regardless of their baseline LDL-C value [44, 117–
119]. As the lipid profile in type 2 diabetes is often 
typical of atherogenic dyslipidaemia (i.e. raised TG 
and lowered HDL-C concentrations), fibrates as an 
add-on therapy to statins may bring an additional 
benefit manifested as a reduced incidence of CV 
events, however evidence in support of this strat-
egy is currently insufficient [50, 51]. It must be 
reCoMMenDATIonS
•	 The recommended management in patients with metabolic syndrome is body weight reduction 
achieved via a change in eating habits and increased physical activity (class of recommendation 
and level of evidence: I A).
•	 Patients with type 2 diabetes and diagnosed CVD or severe CKD, as well as patients over 40 years 
of age with at least one risk factor or organ damage, should receive treatment aimed at a reduc-
tion in LDL-C concentration < 70 mg/dl (< 1.8 mmol/l) and, as a secondary target, a decrease in 
the concentration of non-HDL-C below 100 md/dl (< 2.6 mmol/l) (class of recommendation and 
level of evidence: I b).
•	 Patients with type 2 diabetes without CVD and/or organ damage should receive treatment aimed 
at LDL-C reduction below 100 mg/dl (< 2.6 mmol/l) and, as a secondary target, a decrease in the 
concentration of non-HDL-C below 130 mg/dl (< 3.3 mmol/l), and ApoB below 100 mg/dl (class of 
recommendation and level of evidence: I b).
•	 If statin treatment brings no desirable effect, ezetimibe as an add-on therapy to statins should be 
considered (class of recommendation and level of evidence: IIa b).
•	 In patients with type 2 diabetes, a fibrate can be added to statin therapy when the TG concentra-
tion persists > 200 mg/dl (2.3 mmol/l) (class of recommendation and level of evidence: IIb b).
•	 PCSK9 inhibitors may be considered in patients with diabetes and the LDL-C level persisting > 160 mg/dl 
despite treatment with maximal tolerated statin doses, in combination with ezetimibe or in pa-
tients who are intolerant of statins (class of recommendation and level of evidence: IIb C).
•	 Patients with type 1 diabetes and coexisting microalbuminuria and CKD should be treated with 
statins irrespective of their baseline LDL-C concentration in order to reduce the baseline LDL-C 
concentration by a minimum of 50% (class of recommendation and level of evidence: I C).
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stressed, however, that available evidence comes 
from trials with distinctive methodological lim-
itations, and additional sub-group analyses have 
confirmed the significant status of fenofibrate 
treatment in diabetic patients. In addition, the 
current ESC/EAS guidelines (2016) provide indis-
putably that fibrate therapy may be considered in 
all HTG patients treated with statins when the TG 
levels are > 200 mg/dl (2.3 mmol/l) [32]. 
In patients with type 1 diabetes, the lipid pro-
file may be within the normal range, which can be 
attributed to the beneficial effect of insulin ther-
apy, however their HDL-C particles (so-called dys-
functional HDL) [34] and LDL-C may be potentially 
atherogenic. Patients suffering from type 1 diabe-
tes with coexisting microalbuminuria and chronic 
kidney disease should be treated with statins irre-
spective of their baseline LDL-C levels. The goal of 
treatment in this group should be a decrease in the 
baseline LDL-C value by a minimum of 50% [32].
12.5. Ischaemic heart disease 
Stable ischaemic heart disease
The rules for the treatment of dyslipidaemia 
in patients with IHD (stable angina, history of 
myocardial revascularization, history of myocar-
dial infarction) are no different from the course 
of action, which is undertaken in other patients 
who are at very high CV risk. The central goal in 
dyslipidaemia treatment is the concentration of 
LDL-C, and the target concentration of cholesterol 
depends on its baseline value [6, 32]:
baseline LDL-C level Target LDL-C level
> 135 mg/dl (> 3.5 mmol/l) < 70 mg/dl (> 1.8 mmol/l)
70–135 mg/dl  
(1.8–3.5 mmol/l)
Minimum 50% reduction  
in LDL-C level
The foundation of dyslipidaemia treatment is 
non-pharmacological therapy, however the di-
agnosis of dyslipidaemia should be promptly 
followed by the initiation of pharmacotherapy. 
First-line drugs for the treatment of patients with 
IHD are statins. Hypercholesterolaemia treatment, 
especially in patients who are not in the elderly 
group, should begin with a statin dose that is ex-
pected with a high degree of probability to low-
er cholesterol to the target value. In patients at 
a high risk of adverse effects induced by statins, 
however, treatment should be started at a small 
dose and, after controlling the concentration of 
LDL-C, the dose should be increased, if necessary. 
If statin treatment at a high dose proves ineffec-
tive, another lipid-lowering drug with a  differ-
ent mechanism of action should be added. The 
first choice should be ezetimibe or, alternatively, 
a PCSK9 inhibitor (see Chapter 10.8). If high sta-
tin doses are not tolerated by the patient, a  low 
dose of statin should be used, in the majority of 
cases in combination with another lipid-lowering 
drug such as ezetimibe or, alternatively, a PCSK9 
inhibitor. If the patient develops statin intolerance 
symptoms even in response to low statin doses, 
the therapy should be based on drugs from oth-
er groups (e.g. ezetimibe or, alternatively, a PCSK9 
inhibitor) or their combinations [32]. In isolated 
cases, therapeutic benefits can be obtained with 
fibrates as well as foods enriched with stanols or 
sterols. 
Acute coronary syndrome
All patients hospitalized for acute coronary 
syndrome should be treated with high doses of 
statin in the acute phase of the disease. Therapy 
should be continued or initiated as soon as pos-
sible after hospital admission regardless of the 
baseline LDL-C level. The concentration of LDL-C 
should be checked 4–6 weeks after myocardial 
infarction and the treatment regimen should be 
modified, if required [32]. Further management of 
dyslipidaemia should be the same as in patients 
with stable ischaemic heart disease. 
12.6. Heart failure
Several studies have shown that statin thera-
py in patients with IHD and in primary prevention 
lowers the risk of heart failure (HF) [120]. High-
dose statin therapy, compared to low-dose statin 
key PoInTS To reMeMber
•	 First-line drugs for the treatment of patients 
with ischaemic heart disease are statins. 
•	 The target LDL-C concentration is < 70 mg/dl 
(< 1.8 mmol/l), and in patients with baseline 
LDL-C concentrations in the range of 70–135 
mg/dl (1.8–3.5 mmol/l) it should be reduced 
by a minimum of 50%.
key PoInTS To reMeMber
•	 All patients in the acute phase of the dis-
ease should be treated with a  high-dose 
statin (optimally with rosuvastatin 40 mg or 
atorvastatin 80 mg). Therapy should be con-
tinued or initiated as soon as possible after 
the patient’s hospital admission regardless 
of the baseline LDL-C concentration.
•	 After hospitalization, the target LDL-C concen-
tration is < 70 mg/dl (< 1.8 mmol/l), and in pa-
tients with baseline LDL-C concentrations in 
the range of 70–135 mg/dl (1.8–3.5 mmol/l) 
it should be reduced by a minimum of 50%.
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treatment, has also been demonstrated to reduce 
the risk of hospitalization due to HF in the above 
groups [121]. Patients with advanced forms of 
chronic HF typically have lower cholesterol levels. 
As opposed to individuals without heart failure, 
low cholesterol concentrations in patients suffer-
ing from heart failure are associated with a worse 
prognosis [122, 123]. Although observational 
studies suggest that statins have a beneficial im-
pact on mortality risk in patients with HF, no such 
effect has been confirmed in interventional stud-
ies [122–124].
12.7. Stroke 
Statins used in primary prevention lower the 
risk of stroke by an average of 22% [125]. A sim-
ilar effect of drugs from this group has been 
found in patients after non-cardioembolic stroke 
of ischaemic aetiology [126]. Following stroke 
or transient ischaemic attack (TIA), patients are 
often affected not only by the risk of another 
cerebrovascular event but also other serious CV 
events [6, 32]. Also, patients in this group are 
frequently at a  risk of other conditions of ath-
erosclerotic origin. The aetiology of stroke may 
affect the effects of lipid-lowering treatment. 
The therapeutic benefits may be the greatest in 
patients with atherothrombotic disease causing 
stroke or TIA. In contrast, haemorrhagic stroke 
patients may not benefit from such therapy or 
it may even have a  detrimental effect in them, 
particularly if no evidence for atherosclerosis is 
found [32].
KEY POINTS TO REMEMBER
key PoInTS To reMeMber
•	 Statin-based lipid-lowering therapy should 
not be used in patients in whom the only 
indication is heart failure. 
•	 Continuation of statin treatment should be 
considered in patients with ischaemic heart 
disease.
key PoInTS To reMeMber
•	 Intensive statin treatment should be recom-
mended in patients from high and very high 
risk groups in primary prevention of stroke.
•	 Intensive statin treatment should be rec-
ommended in patients following stroke or 
transient ischaemic attack of ischaemic 
rather than non-cardioembolic aetiology, in 
secondary prevention of stroke.
•	 Lipid-lowering treatment should be recom-
mended in patients with other diseases of 
atherosclerotic origin in primary prevention 
of stroke. 
12.8. Chronic kidney disease 
Since patients with chronic kidney disease 
(CKD) are at a very high CV risk, the initiation of 
statin treatment is based on the evaluation of to-
tal CV risk in accordance with prevention guide-
lines [6]. At the same time, on the basis of data 
from the Alberta Kidney Disease Network, it must 
be noted that the direct correlation between CV 
risk and LDL-C is weaker in patients with CKD not 
receiving dialysis therapy than in the general pop-
ulation [127]. The finding above can be attributed 
to an increased role of atherogenic dyslipidae-
mia in patients with CKD, which is characterized 
by lower LDL-C and higher sdLDL concentrations, 
a  decrease in HDL and an increase in TG con-
centrations. Therefore, the LDL-C concentration 
alone may be less helpful for making decisions 
on the implementation of treatment in patients 
with advanced chronic kidney disease not requir-
ing dialysis therapy [127]. The decision should 
depend on the evaluation of total cardiovascular 
risk taking into account the patient’s age, and the 
degree of kidney failure and/or estimated glo-
merular filtration rate (eGFR) [127, 128]. Based 
on such evaluation the incidence of fatal CVD 
and non-fatal myocardial infarction in patients 
with CKD aged > 50 years, both men and women, 
exceeds 10/1,000, which justifies the indication 
of a  potential benefit of statin treatment [127, 
128]. The KIDIGO (Kidney Disease: Improving 
Global Outcomes) guidelines define statin doses, 
which are optimal for different stages of chronic 
kidney failure rather than for different LDL-C lev-
els. Drugs eliminated via liver metabolism (ator-
vastatin, fluvastatin, pitavastatin, ezetimibe) are 
the preferred option in this patient group. Statins 
metabolized by CYP3A4 may lead to side effects 
due to multiple drug interactions, and are not 
recommended [129, 130]. 
Benefits of statin therapy have been noted in 
patients with stage 2 and 3 CKD (based on Pravas-
tatin Pooling Project – 19,737 patients followed up 
for an average of 64 months, and the largest study 
investigating statins – Heart Protection Study). The 
greatest benefits are noted in patients with coex-
isting CKD and diabetes [131]. There is no clear 
evidence to conclude beyond doubt that statin 
or statin/ezetimibe therapy is beneficial in adults 
with stage 5 CKD undergoing dialysis treatment. 
Cardiovascular mortality in this patient group is 
mainly associated with heart failure and cardiac 
dysrhythmia [131, 132]. However, treatment con-
tinuation is indicated in those patients who were 
treated for dyslipidaemia at the time of starting 
dialysis therapy.
Full lipid profiling is recommended at an ear-
ly stage in patients with CKD, mainly in order to 
identify severe forms of hypercholesterolaemia 
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and hypertriglyceridaemia, and rule out modifia-
ble/secondary causes of dyslipidaemia [32]. Lipid 
profile control is recommended only if it affects 
clinical decisions, e.g. for the purpose of monitor-
ing the patient’s compliance with statin therapy 
or determine 10-year CV risk in younger patients 
with CKD who are not currently treated with 
a  statin [32]. It needs to be noted that recom-
mendations for the treatment of dyslipidaemia in 
chronic kidney disease are based solely on a few 
large RCTs, meta-analyses and post-hoc analyses 
of patient subgroups from large clinical trials of 
statins.
Summing up, the level of CV risk in patients with 
stage 3–5 chronic kidney disease is considered to 
be very high (see Table V). Intensive statin and/or 
ezetimibe treatment is recommended in patients 
not requiring dialysis therapy. Statins should not 
be used, or should be used with extreme caution, 
in patients who undergo dialysis but are free from 
CVD induced by atherosclerosis [32]. 
12.9. Peripheral vascular disease 
Atherosclerotic lesions are the predominant 
cause (over 95% of cases) of chronic lower limb 
ischaemia. Often, the symptoms of lower limb 
ischaemia including intermittent claudication are 
the first clinical manifestation of systemic ath-
erosclerosis [32]. It is currently known that ath-
erosclerotic lesions in peripheral arteries are an 
independent factor contributing to the risk of CV 
events including acute coronary syndrome and 
stroke. Such patients require active pharmaco-
logical and non-pharmacological management in 
order to improve their outcome. Lipid-lowering 
therapy in this patient group has been shown not 
reCoMMenDATIonS
•	 Patients with stage 3–5 chronic kidney dis-
ease are classified as being at high or very-
high CV risk (class of recommendation and 
level of evidence: I A).
•	 Statins alone or in combination with ezeti-
mibe are recommended in patients not re-
quiring dialysis therapy (class of recommen-
dation and level of evidence: I A).
•	 Statins are not recommended in patients 
who require dialysis therapy but have not 
been diagnosed with cardiovascular diseas-
es (class of recommendation and level of 
evidence: III A).
•	 If a patient treated with a statin or statin/
ezetimibe combination requires dialysis 
therapy, the continuation of statin treatment 
is recommended (class of recommendation 
and level of evidence: IIa C).
only to inhibit the progression of atherosclerosis 
in the peripheral arterial bed but also to reduce 
the risk of serious events in other beds (coronary, 
cerebral) [6]. A meta-analysis of 18 clinical trials 
encompassing over 10,000 patients with lower 
limb atherosclerosis has shown that lipid-lower-
ing therapy leads to a nearly 20% reduction in the 
risk of CV events and a 14% decrease in all-cause 
mortality [32, 133].
12.10.  Autoimmune, rheumatic  
and inflammatory diseases 
Autoimmune, rheumatic and inflammatory 
diseases are accompanied by an increase in the 
risk of CVD, which is not always associated with 
elevated TC and LDL-C levels (a phenomenon re-
ferred to as lipid paradox) [134]. An increased CV 
risk which is present in a number of diseases – in-
cluding systemic lupus erythematosus, psoriasis, 
psoriatic arthritis, antiphospholipid syndrome, 
rheumatoid arthritis, ankylosing spondylitis, ul-
cerative colitis or Crohn’s disease – is linked to 
vasculitis and endothelial dysfunction, and conse-
quently to an increased severity of atherosclero-
sis [135–137]. Consequently, patients with these 
diseases have higher CV morbidity and mortal-
ity rates compared with the general population 
[138]. There are currently no indications for the 
preventive use of lipid-lowering drugs only on the 
basis of the presence of autoimmune, rheumatic 
or inflammatory diseases, and measures for the 
prevention and treatment of dyslipidaemia do not 
differ from generally applicable rules. It should 
be noted, though, that autoimmune, rheumatic 
and inflammatory diseases can be accompanied 
by increased concentrations of lipid parameters 
secondary to anti-inflammatory treatment of the 
diseases [139]. 
key PoInTS To reMeMber
•	 The therapeutic goals in patients with pe-
ripheral atherosclerosis are the same as in 
other patients in the group of very high risk 
(LDL-C < 70 mg/dl (< 1.8 mmol/l) or LDL-C 
reduction by a minimum of 50% at the base-
line LDL-C level of 70–135 mg/dl (1.8–3.5 
mmol/l)), and drugs of choice are statins at 
maximal tolerated doses. 
•	 Non-pharmacological lifestyle modifications, 
including cessation of smoking, physical ac-
tivity, walking training, etc., are also very 
important, as they have a  beneficial effect 
on the lipoprotein level and also stimulate 
the development of collateral circulation 
and improve the metabolism of ischaemic 
muscles.
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12.11. Pregnancy and breast-feeding
Statin treatment should be discontinued in 
women at least 3 months before a planned preg-
nancy, during pregnancy and lactation [140]. 
Statins are teratogenic, and are rated as cat-
egory X drugs, meaning that the risks they in-
volve markedly outweigh any benefits. However, 
the risk of foetal damage in women receiving 
chronic statin treatment is not high, so in the 
case of accidental pregnancy women should be 
reassured, and their gynaecologist/obstetrician 
must be informed immediately [141, 142]. The 
only lipid-lowering drugs, which are safe to use 
during pregnancy are ion-exchange resins (cur-
rently unavailable in Poland) [143]. The best-tol-
erated resin is colesevelam. The continuation of 
LDL-apheresis in pregnant women with hoFH is 
both safe and indicated [140, 143]. Contraceptive 
methods, which are indicated in women of repro-
ductive age diagnosed with FH [140] include low-
dose oestrogen oral contraceptives, intra uterine 
devices (IUDs) and condoms. Since high-dose 
oestrogen oral contraceptives may increase the 
concentrations of TG and LDL-C, it is crucial to 
monitor the lipid profile in women with FH who 
take medications of this kind. In addition, medi-
cal consultations should be provided to all wom-
en of reproductive age whose parents have been 
diagnosed with FH, as the risk of homozygous FH 
in their children is as high as 25% [140–145].
key PoInTS To reMeMber
•	 There are no indications for the preventive 
use of lipid-lowering drugs only on the ba-
sis of the presence of autoimmune diseases, 
and measures for the prevention and treat-
ment of dyslipidaemia do not differ from 
generally applicable rules.
•	 Before initiating dyslipidaemia treatment in 
individuals with autoimmune and rheumatic 
diseases it should be noted that the evalu-
ation of CV risk in this patient group on the 
basis of the traditional SCORE system may 
not be sufficient, and the actual risk level 
may be higher than estimated.
12.12. Cognitive disorders
The treatment of lipid disorders in patients 
with cognitive disorders is a particularly difficult 
challenge both in the context of pharmacotherapy 
of dyslipidaemia (interactions with other drugs), 
patient compliance and data showing that a very 
substantial decrease in LDL-C may potentially lead 
to an exacerbation of cognitive disorders. The 
problem has been omitted in a range of key guide-
lines [129], however as awareness is growing, it 
requires a cautious approach and close monitor-
ing during therapy. Small observational studies in-
dicate that statins have a protective effect on the 
development of cognitive disorders [32]. Although 
it can be noted at very remote follow-up due to 
vascular protective effects of the drugs, most 
data derived from randomized and observational 
studies fail to confirm the efficacy of statin treat-
ment in preventing the development of cognitive 
disorders in elderly patients [146]. Isolated data 
from observational studies point to such benefits 
in patients with type 2 diabetes [147] and atrial 
fibrillation [148], which may result from the effect 
of cognitive disorders on drug use, not the other 
way round [146]. There are, as yet, no reliable data 
describing the impact of long-term statin use on 
the development of cognitive disorders at a later 
time, and mechanisms proposed to account for 
such impact fail to fully confirm the correlation 
[149]. A potential protective effect of statins can-
not be excluded at this stage, either.
12.13.  HIV/AIDS, terminal diseases, 
palliative states
Terminal diseases and palliative states require 
a cautious assessment of benefits and the poten-
tial risk of side effects in dyslipidaemia treatment 
[4, 98]. Since patients with these conditions have 
typically been excluded from large randomized 
clinical trials, scientific evidence is weak, and 
leads to controversies and differences in the ap-
proach recommended in guidelines published to 
date. Recent studies have also demonstrated that 
the discontinuation of statin treatment in pallia-
tive patients is not associated with a  deteriora-
key PoInTS To reMeMber
•	 Patients with cognitive disorders should be 
subject to all standard recommendations for 
the treatment of dyslipidaemia depending 
on the lipid levels, coexisting diseases and 
total cardiovascular risk.
•	 Monitoring of patient compliance and side 
effects is recommended, involving the pa-
tient’s carers, if practicable.
key PoInTS To reMeMber
Lipid lowering treatment should be discon-
tinued in women at least 3 months before 
a  planned pregnancy, during pregnancy and 
lactation. The only lipid-lowering drugs, which 
are safe to use during pregnancy are ion-ex-
change resins (currently unavailable in Po-
land). 
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tion of CV parameters including mortality. In fact, 
it has been noted to bring about a significant im-
provement in the quality of life in these patients 
[150]. The data are still insufficient to draw any 
definite conclusions, however an individual pa-
tient approach should sometimes be considered, 
always bearing in mind that the discontinuation 
of statin treatment may entail an increase in the 
risk of CV events [4, 5]. 
Preliminary and small studies do not point to 
an increased hepatotoxicity of statins in patients 
from these groups, though special attention should 
be paid to potential drug interactions, especially in 
view of the fact that these patients often take multi-
ple medications. A particular focus should be placed 
on interactions between statins and protease inhib-
itors in HIV patients due to the CYP3A4 metabolism, 
leading to an elevated risk of myopathy and rhab-
domyolysis [32]. While TC and LDL-C concentrations 
in the patient groups listed above are often reduced, 
treatment may have an adverse impact on the lipid 
profile. Highly active antiretroviral therapy (HAART), 
mainly consisting of protease inhibitors, has a neg-
ative effect on the lipid profile, particularly on the 
development of atherogenic dyslipidaemia [151]. 
Following a  diagnosis of dyslipidaemia, a  change 
of drugs used in HAART may be considered. Alter-
natively, pravastatin may be considered as a drug, 
which is recommended in HIV patients because it 
is only minimally metabolized by the P450 cyto-
chrome isoenzyme system. Aside from pravastatin, 
other drugs, which may be considered include ator-
vastatin, rosuvastatin, pitavastatin (unavailable in 
Poland) and fluvastatin. Detailed information about 
drug interactions in HIV patients is available at 
www.hiv-druginteractions.org. Combining simvas-
tatin or lovastatin with protease inhibitors or with 
efavirenz (NNRTI – non-nucleoside reverse tran-
scriptase inhibitor) is not recommended. 
Also, attention should be paid to the fact that 
the level of CV risk in HIV patients is higher (even 
above 60%) than in HIV-free patients, and an-
tiretroviral drugs, especially protease inhibitors, 
cause an up to twofold increase in that risk [32]. 
Similarly, in cancer patents the pleiotropic activ-
ity of drugs used for dyslipidaemia and optimal 
lipid profile control may be crucial for preventing 
a marked rise in CV risk, for example in patients 
who have completed chemotherapy [152]. 
12.14. Liver diseases
For years, elevated aminotransferase levels 
were recognised by physicians as a  contraindi-
cation to statin therapy. As a  result, patients at 
high CV risk frequently received no lipid-lowering 
treatment at all [5]. However, further experimental 
and clinical studies as well as cohort observations 
showed that the direct mechanisms potentially 
responsible for hepatocyte damage secondary to 
statin therapy were in fact unknown, whereas the 
phenomenon of a symptomless increase in ami-
notransferase level accompanying statin treat-
ment was rare (< 1%) and transient in nature [5]. 
In February 2012, FDA was the first institution to 
recommend that liver enzyme tests (ALT – alanine 
transaminase) should be performed prior to the 
initiation of therapy, while routine monitoring 
throughout therapy is necessary only in the event 
of clinical symptoms [5]. The view was upheld by 
other associations and in expert opinions includ-
ing the International Lipid Expert Panel (ILEP) [5] 
or the recent ESC/EAS 2016 guidelines [32].
Furthermore, available studies indicate that 
statin therapy should be continued and benefits 
can be achieved even by patients with hepatitis 
induced by hepatitis B virus (HBV) and hepatitis C 
virus (HCV), though not in acute and active forms 
of the disease [5, 153]. Potential therapeutic ben-
efits comprise a  significant decrease in the risk 
of hepatocellular carcinoma by up to 28% in HBV 
and HCV patients, or a reduction in the incidence 
of hepatitis C virus in the blood achieved through 
inhibiting its replication [5, 154]. 
Available studies also point to the beneficial 
role of statins in patients with primary biliary cir-
rhosis (PBC) in terms of improved course of the 
disease but primarily in terms of CV risk reduction 
in this patient group [5]. Even greater therapeutic 
benefits can be noted in patients with non-alco-
holic fatty liver disease (NAFLD) and non-alco-
holic  steatohepatitis (NASH), which are diseases 
currently leading to liver cirrhosis more often than 
alcoholic disease [5]. The diseases are frequently 
accompanied by hypertriglyceridaemia with a re-
duced level of HDL-C and an increased incidence 
of atherogenic VLDL and LDL lipoprotein subfrac-
tions [5]. Available studies have found statin ther-
apy to be very effective at reducing CV morbidity 
and mortality in the group of NAFLD patients com-
key PoInTS To reMeMber
•	 The treatment in patients with HIV/AIDS, 
cancerous diseases and palliative states 
should be adjusted to the level of CV risk 
and the benefits, which can be achieved by 
the patient in long-term therapy. 
•	 The therapeutic targets should correspond 
to the targets of therapy defined for patients 
who are at high CV risk. 
•	 Since non-pharmacological management is 
insufficient in the majority of HIV patients 
receiving antiretroviral treatment, the addi-
tion of statins should be considered in their 
treatment. In patients who are intolerant of 
statins the therapeutic option is ezetimibe. 
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pared to patients not receiving statin treatment 
(68 vs. 39%, p = 0.007) [154]. Study results also 
show that statin therapy in these patient groups 
is safe [5, 32]. Consequently, low-dose statin 
treatment may be considered in NAFLD or NASH 
patients with baseline ALT concentrations > 3 × 
upper limit of normal (ULN), however their ALT 
levels must be monitored on a monthly basis for 
3 months, and four times a year afterwards. The 
therapeutic management in chronic liver diseases 
is described in Chapter 14.
13.  ADVerSe eFFeCTS ASSoCIATeD  
WITH DySLIPIDAeMIA TreATMenT/STATIn 
InToLerAnCe
Statin intolerance is a  phenomenon which 
has been observed for many years, however it 
has lately become a focus of interest due to the 
introduction of new drugs for combined therapy 
(primarily ezetimibe and PCSK9 inhibitors but also 
ETC-1002) and studies investigating the ineffica-
cy of statin treatment with an emphasis on statin 
nonresponse, statin non-adherence, statin discon-
tinuation or statin intolerance [4, 5, 155]. Statin 
intolerance should be defined as the lack of possi-
bility to use a statin therapy – both with respect to 
a statin drug and its dose – that would be appro-
priate for the existing cardiovascular risk [5, 32]. 
In other words, statin intolerance refers not only 
to the lack of statin treatment because of clini-
cal or biochemical symptoms (so-called complete 
intolerance) but also to the treatment with insuf-
ficiently high statin doses or with insufficiently 
potent statins in relation to the CV risk level [5, 
156]. In March 2015, the International Lipid Expert 
Panel (ILEP) proposed the following definition of 
statin intolerance:
1. inability to tolerate at least 2 different statins – 
one statin at the lowest starting average daily 
dose and the other statin at any dose, 
key PoInTS To reMeMber
•	 Liver enzyme tests (ALT) should be per-
formed prior to the initiation of treatment, 
while routine monitoring throughout ther-
apy is not necessary (indicated only in the 
event of clinical symptoms).
•	 Due to beneficial effects on the course of 
the disease and its complications, and a de-
crease in CV risk, statin treatment should be 
used in patients with hepatitis B and C.
•	 Statin therapy is safe in patients with NA-
FLD/NASH; it contributes to an improved 
course of the disease, and reduces the CV 
risk in a much more significant manner than 
in individuals with normal liver function.
2. intolerance associated with confirmed, intoler-
able statin-related adverse effect(s) or signifi-
cant biomarker abnormalities, 
3. symptoms or biomarker changes resolution or 
significant improvement upon dose decrease 
or discontinuation, 
4. symptoms or biomarker changes not attrib-
utable to established predispositions such as 
drug-drug interactions and recognized condi-
tions increasing the risk of statin intolerance [5]. 
It needs to be noted that there are multiple 
risk factors which may increase the likelihood of 
statin intolerance including physical activity, par-
ticularly after its initiation or increase in intensi-
ty; hepatic and/or renal diseases, hypothyroidism, 
vitamin D deficiency [157], alcohol intake, rheu-
matic diseases, extensive surgical procedures, 
low body weight, female gender or old age [5, 
158]. The consensus prepared by ILEP addressed 
in detail all the risk factors enumerated above, 
and presented patient management recommen-
dations aimed at reducing the risk of intolerance 
and ensuring the possibility to continue statin 
therapy [5]. 
A discussion of the problem of statin intoler-
ance should involve several key aspects. In 90% 
of cases, symptoms of intolerance develop with-
in the initial 6 months after starting therapy or 
increasing the statin dose, and in 75% of cases 
– during the initial 12 months of therapy. The 
likelihood of intolerance symptoms developing 
a year after the start of therapy or dose increase 
is low, unless a  risk-increasing factor (disease, 
new drug interacting with statins) emerges [5, 
158]. The most common causes of statin intoler-
ance are muscle symptoms (affecting up to 29% 
of patients) [158] manifested as pain (myalgia), 
contractions, muscle weakness with or without 
an accompanying increase in the level of creatine 
kinase (CK) (myopathy), with or without muscle 
inflammation (myositis). Myonecrosis and rhab-
domyolysis occur extremely rarely (< 2/100,000 
patient-years) and may frequently be linked to 
a genetic predisposition, an exacerbation of con-
comitant disease or a  therapeutic error [5, 32, 
156, 158]. Other symptoms of statin intolerance 
including hair loss, sleep disorder [159], influ-
enza-like symptoms, lupus-like symptoms, skin 
rashes, gastrointestinal symptoms, decreased li-
bido or gynecomastia are rare, and it is often diffi-
cult to attribute them directly to statin treatment. 
Furthermore, available studies fail to show any 
causality between statin therapy and symptom 
development [5]. Excluding individual risk factors 
which may lead to statin intolerance, attention 
should always be paid to the so-called “nocebo 
effect”, where patients starting statin treatment 
actually expect the development of symptoms 
based on information about possible adverse ef-
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fects found in the patient information leaflet or 
via the internet, or received from other patients 
taking the same medications [5, 156]. In most 
cases, such symptoms can be easily eliminated by 
collecting a detailed history from the patient (in-
cluding the onset of symptoms, their location and 
severity). In statin-intolerant patients, appropri-
ate management (step-by-step approach involv-
ing proper history taking and gradual exclusion of 
causes underlying statin intolerance, prompt in-
troduction of appropriate measures) may enable 
the continuation of statin therapy in over 90% of 
these patients. Consequently, complete statin in-
tolerance is a rare phenomenon, occurring only in 
1–2% of cases [5, 156]. 
The following patient management is recom-
mended in the event of statin intolerance [5, 32, 
158]:
1. If the patient reports muscle pain at CK ≥ 4 ULN, 
statin treatment should be discontinued for 
4–6 weeks until the regression of pain and CK 
normalization.
2. If the patient reports tolerable muscle pain 
at CK < 4 ULN, a reduction in statin dose and 
treatment continuation with close monitoring 
of CK may be considered; if clinical symptoms 
are exacerbated and/or the CK concentration 
is increased, statin treatment should be dis-
continued for 4–6 weeks until the regression of 
pain and CK normalization.
3. If the patient reports intolerable muscle pain 
at CK < 4 ULN, statin treatment should be dis-
continued for 2–4 weeks until the regression of 
pain and CK normalization.
4. Following the regression of symptoms/CK nor-
malization, treatment with another highly ef-
fective statin (preferably atorvastatin or rosu-
vastatin) should be initiated at an appropriately 
reduced dose, so that after 4–6 weeks, if the 
patient experiences no symptoms, the starting 
dose adjusted to the patient’s risk level can be 
resumed (applicable to item 1) or another sta-
tin at a corresponding dose (in accordance with 
Roberts’ rule) adjusted to the patient’s risk lev-
el can be introduced (applicable to item 3).
5. If intolerance symptoms persist, options that 
may be considered include a further reduction 
in statin dose, statin administration every other 
day, 1–2 times per week (with a proven efficacy 
for atorvastatin and rosuvastatin) or the addi-
tion of ezetimibe to an appropriately adjusted 
statin dose. In cases of complete statin intoler-
ance the addition of fenofibrate to ezetimibe 
treatment may be considered. 
6. PCSK9 inhibitors may be considered in patients 
at high and very high CV risk, with persistently 
high LDL-C concentrations in statin-intolerant 
patients. 
14.  reCoMMenDATIonS For MonITorInG 
LIPIDS AnD bIoCHeMICAL PArAMeTerS 
DurInG DySLIPIDAeMIA TreATMenT
The side effects associated with statin use, 
and the management recommended after their 
development, are described in detail in the 
opinion of the ILEP, while statin-induced muscle 
symptoms – in the EAS Consensus Panel state-
ment [158]. The present section is based on the 
documents referred to above and on recommen-
dations provided in the most recent (2016) ESC/
EAS guidelines for the management of dyslipi-
daemias [32].
Lipid profiling should be performed 8 ±4 weeks 
after the initiation of pharmacotherapy and with-
in the same time frame if the drug or the drug 
dose is modified. The most common side effects 
of statin therapy are statin-associated muscle 
symptoms (SAMS). They can be serious (myopa-
thy and rhabdomyolysis) and milder, manifested 
as muscle contractions and pain (myalgia) and/or 
muscle weakness. Myopathy can be accompanied 
by an increase in the level of creatine kinase (see 
Chapter 13). Postulated pathomechanisms for 
muscle symptoms include mitochondrial dysfunc-
tion, reduced energy generation or muscle protein 
degradation [48, 160]. 
It is recommended to determine the CK level 
before the introduction of a  statin (also a  fibra-
te). There is no need to perform routine CK tests 
during therapy. The only indications for CK test-
ing are muscle complaints. Myopathy can be 
associated with a  rise in CK levels, however the 
symptom may also be absent. Rhabdomyolysis 
is characterized by a marked increase in the lev-
el of the enzyme, myoglobinemia, myoglobinuria 
(dark urine), acute renal failure (oliguria, increase 
in the concentration of creatinine ≥ 0.5 mg/dl and 
potassium). Consequently, the emergence of se-
vere muscle symptoms accompanied by a  high 
increase in CK should be followed by the evalu-
ation of symptoms and biochemical parameters, 
and immediate hospital referral [32, 158]. In the 
event of muscle symptoms, EAS suggests the fol-
lowing course of action: discontinuation of statin 
therapy for 6 weeks and, after a  treatment-free 
period, introduction of one or two other statins – 
also with a 6-week interval between them [158]. 
The above strategy makes it possible to verify 
whether the muscle complaints are statin-asso-
ciated, in which case they subside after the dis-
continuation of treatment and return after using 
another drug from this group. In SAMS patients, 
experts suggest a  statin at a  maximal tolerated 
dose in combination with another lipid-lowering 
agent – or a non-statin drug. The preferred option 
is ezetimibe, followed by an anion exchange resin 
(colesevelam – unavailable in Poland) or a fibrate 
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[32, 158]. An alternative option is to use PCSK9 
inhibitors [32]. 
According to ESC/EAS experts, statin discontin-
uation is indicated if the CK level is > 10× ULN, 
and CK is 4–10× ULN, if accompanied by muscle 
symptoms [32]. In the former case, the patient’s 
renal function should be examined and CK should 
be monitored every 2 weeks. In the latter case, CK 
should be monitored until its normalization and 
followed by the introduction of another statin at 
a lower dose. If the CK level is < 10× ULN, and no 
muscle symptoms are observed, the therapy can 
be continued, while monitoring the CK levels. The 
treatment should also be discontinued if the pa-
tient finds the symptoms intolerable, even though 
the CK is in the normal range [32]. 
Statin-induced liver damage is a very rare oc-
currence. The general rule should be to determine 
the concentration of aminotransferases (ALT) be-
fore starting treatment. There is no need to mon-
itor enzyme activity during therapy on a  routine 
basis. However, the test should be performed if 
the patient develops symptoms indicative of hep-
atotoxicity (pain, unusual fatigue, weakness and 
jaundice). The symptoms listed above and/or an 
increase in ALT over 3× ULN, are an indication for 
discontinuing the therapy. Statins are not used in 
patients with acute hepatitis. Chronic liver diseas-
es are not regarded as contraindications, however 
experts recommend liver enzyme monitoring on 
a monthly basis for the initial 3 months after drug 
use, and four times a year afterwards [32, 158]. If 
the baseline values are found to have increased 
≥ 2×, ILEP experts recommend the discontinuation 
of statin treatment. Following the normalization 
of liver enzyme levels, therapy should be initiated 
with a different statin drug [5].
Experts recommend thyroid-stimulating hor-
mone (TSH) testing before the initiation of statin 
treatment, as hypothyroidism is a  risk factor for 
myopathy. Although statins exhibit a diabetogen-
ic effect, there is no recommendation to evaluate 
the level of glycaemia before and during treat-
ment, as even the development of diabetes is not 
an indication for discontinuing the use of the drug. 
In our view, periodic glycaemic tests are neverthe-
less beneficial, particularly in individuals with risk 
factors predisposing to the development of diabe-
tes (e.g. carbohydrate disorders, obesity) [161]. In 
fibrate-treated patients, in addition to baseline CK 
and aminotransferase tests, creatinine concentra-
tion should also be determined [32]. 
15.  CAuSeS oF IneFFeCTIVe TreATMenT  
oF DySLIPIDAeMIAS 
Dyslipidaemia is one of the main modifiable 
risk factors for cardiovascular diseases. The pri-
mary biochemical target in the treatment of dys-
lipidaemias is to effectively lower the concentra-
tion of the LDL fraction [6, 32]. According to the 
current recommendations, the target in patients 
from high CV risk groups is to reduce their LDL-C 
level below 100 mg/dl (2.6 mmol/l), and in pa-
tients from very high-risk groups – below 70 mg/dl 
(1.8 mmol/l) or by a minimum of 50% relative to 
the baseline values [32]. This scale of reduction in 
the concentration of LDL-C can be achieved only 
by introducing an intensive lipid lowering treat-
ment (atorvastatin at 40–80 mg a  day, rosuvas-
tatin at ca. 20–40 mg a day or maximal doses of 
weaker statins) [32]. In monotherapy, aside from 
atorvastatin or rosuvastatin, a decrease in LDL-C 
by 50% of its baseline value can only be achieved 
with simvastatin at a  daily dose of 80 mg. The 
dose, however, is not currently recommended, 
since the risk of adverse effects and intolerance 
of treatment markedly outweighs potential bene-
fits resulting from therapy. It must be remembered 
that the tolerance of dyslipidaemia treatment is as 
important as its efficacy. Dyslipidaemia is a chron-
ic and intrinsically symptomless disorder. Each 
40 mg/dl (1 mmol/l) decrease in LDL-C concentra-
tion is known to translate into a 20% relative re-
duction in fatal cardiovascular disease and a 17% 
decrease in the risk of stroke [32, 49]. 
However, there is no direct correlation be-
tween successful treatment and the patient’s 
well-being. Rather, the success of therapy is ex-
pressed as a  percentage of eliminated potential 
CV events. Ultimately, then, the success of ther-
apy is crucially dependent on the establishment 
key PoInTS To reMeMber
•	 The concentration of lipids should be as-
sessed 4–8 weeks after the initiation of 
pharmacotherapy, following a  change in 
drug dose or a change of drug.
•	 The most common side effects of statins are 
muscle complaints. Statin-induced hepato-
toxicity is very rare. 
•	 Statins have diabetogenic properties, how-
ever an increased glucose concentration (or 
even the development of diabetes) is not 
a  reason for discontinuing the use of the 
drug, as the benefit (i.e. risk reduction) out-
weighs the harm.
•	 Before a  statin is used, it is recommended 
to assess the concentrations of CK, ALT and 
TSH. Before introducing a  fibrate, CK and 
ALT/AST as well as creatinine levels should 
also be assessed.
•	 There is no need to monitor the CK and ALT 
levels on an ongoing basis, however the 
tests are recommended if the patient has 
muscle or liver symptoms.
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of appropriate physician-patient relationships, so 
that the patient is able to properly understand 
the goal and expected effects of treatment. The 
physician-patient relationship is increasingly fre-
quently described with reference to such terms as 
compliance, adherence or persistence. Initially, the 
terms were used mainly in the context of thera-
py of arterial hypertension, however they are also 
perfectly suited for addressing problems related to 
the efficacy of dyslipidaemia treatment.
15.1. Compliance
In medical contexts, compliance refers to the 
observance of medical advice or adherence to the 
physician’s recommendations. In this sense, how-
ever, the term may have negative connotations. 
Furthermore, it reduces the patient’s role in the 
treatment process to following the physician’s 
orders/recommendations. Based on other sourc-
es, compliance can be understood as the “degree 
of adherence to medical recommendations” [32, 
155]. The term is thus very broad and difficult to 
define precisely. In simple terms, the quality of 
compliance can be determined on the basis of 
the efficacy of treatment of a given condition – in 
this case dyslipidaemia. Over the past few years, 
the efficacy has improved. Based on the results 
obtained in the 3ST-POL trial conducted in 2007–
2008, the recommended concentrations for total 
cholesterol were achieved in nearly 10% of pa-
tients with risk factors and nearly 16% of patients 
without risk factors, and target LDL levels – in 
15.6% and 22.7% of patients, respectively. The tri-
al included only patients treated on an outpatient 
basis [162]. In the same period, according to the 
Polish results of the EUROASPIRE study, the target 
concentration of total cholesterol was achieved in 
up to 70% of patients, and the target concentra-
tion of LDL-C – in 39% of patients [163]. More re-
cent studies focused on the efficacy of treatment 
in Poland, such as CEPHEUS carried out in 2011–
2012, are more optimistic, with target LDL-C con-
centrations achieved in approx. 50% of patients 
treated in secondary or primary prevention [164]. 
At the same time, however, the mean reduction 
in LDL-C concentration in the CEPHEUS study was 
only 20% compared to the baseline value [164]. 
Consequently, the efficacy of dyslipidaemia treat-
ment in Poland definitely persists at a level, which 
is far from satisfactory.
15.2.  Adherence, non-response (non-
adherence) and persistence 
Adherence and persistence are two other terms 
describing selected aspects of the physician-pa-
tient relationship [155]. Adherence is usually 
understood as the patient’s cooperation in fol-
lowing therapeutic recommendations, whereas 
persistence stands for perseverance in continu-
ing therapy. Other terms frequently used in this 
context are non-adherence and non-response, 
referring to failure to adhere to therapeutic rec-
ommendations (the concept of non-response is 
also used to describe the patient’s inappropriate 
response to statin treatment, i.e. situations where 
no LDL-C reduction is observed or the reduction is 
lower than expected [165]). In simple terms, pa-
tients are asked whether they comply with thera-
peutic recommendations and to what extent they 
follow the prescribed treatment regimen. Polish 
data describing this aspect are not optimistic, 
either. According to the 3ST-POL trial [162] 25% 
of patients stopped taking statins as early as 
3 months after the initiation of treatment. After 
3 years, therapy was continued only by 15% of pa-
tients. In the CEPHEUS study [164], approximately 
92% of patients declared taking “cholesterol-low-
ering” drugs every day. At the same time, however, 
18% of subjects forgot to take their medication 
once a  month, about 10% – once per 2 weeks, 
and about 3.5% – more often than once a week. 
In addition, almost one in 10 patients admitted 
stopping treatment after the achievement of 
target cholesterol levels. Only 83.6% of patients 
declared taking statins a year after their hospital-
ization for acute coronary syndrome or myocardial 
revascularization. Furthermore, the average doses 
of statins they declared using were far from ex-
pected – rosuvastatin 14.6 mg/dl and atorvastatin 
32.8 mg/dl [21].
Treatment discontinuation is a  very serious 
problem, and an error committed by patients and 
physicians. It is also potentially dangerous, partic-
ularly in patients classified as being at high and 
very high risk, due to the possibility of atheroma-
tous plaque instability and the risk of (another) 
cardiovascular event [4, 32]. Studies have shown 
that the discontinuation of treatment is linked 
to a threefold increase in all-cause mortality and 
a  fourfold rise in cardiovascular mortality [166]. 
Achieving the target concentration of LDL-C with 
a good tolerance of the drug dose used represents 
a  proof that the treatment strategy is effective 
and shows indisputably that the therapy should 
be maintained. In such circumstances, stopping 
the treatment or reducing the statin dose may 
lead to a rapid rise in the concentration of LDL-C 
and, as a result, increase the level of CV risk.
15.3. Therapeutic inertia 
The role of the physician in the therapeutic pro-
cess is naturally fundamental. In the treatment 
of dyslipidaemias, the physician estimates the 
patient’s total cardiovascular risk, verifies indi-
cations for the introduction of pharmacotherapy, 
selects a  specific drug (or drugs), and monitors 
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the safety and efficacy of the adopted patient 
management regimen. The phenomenon of the 
so-called therapeutic inertia has been observed in 
Poland, particularly in outpatient treatment facil-
ities, for many years. In dyslipidaemia treatment, 
the problem manifests itself primarily as:
•	 Belittling the importance of non-pharmacologi-
cal management;
•	 Unjustified deferral in the introduction of phar-
macotherapy for dyslipidaemia; 
•	 Use of statin doses which are too low in rela-
tion to the adopted therapeutic targets;
•	 Lack of statin dose modifications if the treat-
ment is ineffective;
•	 Unjustified interruption of statin treatment;
•	 Apprehension about using combined therapy.
Analyzing therapeutic inertia, attention should 
be focused again on the outcomes of the 3ST-POL 
and CEPHEUS studies [162, 164]. Despite a 4-year 
interval between them, the average doses of the 
most commonly used statins were comparable in 
both studies: about 20 mg daily for atorvastatin and 
simvastatin. In the CEPHEUS study [164], 90% of the 
subjects took one lipid-lowering drug (statin), and 
only ca. 6% of the patients were on combined ther-
apy. However, a year after hospitalization for acute 
coronary syndrome or myocardial revascularization 
only 0.5% of patients declared using a statin with 
ezetimibe, and 1.9% – a statin and fibrate combina-
tion [21]. Despite ongoing debates and some con-
cerns about available data, combinations of a statin 
and fibrate, and a statin and ezetimibe, are not only 
effective (both in the context of biochemical effects 
and specific patient groups – in the clinical context) 
but also safe and well-tolerated. The signatories of 
the Sopot Declaration [167] have stated clearly that 
a combined therapy of dyslipidaemias is used too 
rarely in Poland. Finally, it needs to be noted that 
lipid profiling should be performed every 6–8 weeks 
until the achievement of target concentrations of 
different lipid fractions. The common practice in 
outpatient treatment, however, is based on fixed 
doses of statins without biochemical monitoring of 
treatment results [6, 32, 168].
16.  orGAnIzATIon oF PoLISH HeALTHCAre 
In DySLIPIDAeMIAS
The main burden in the prophylaxis, preven-
tion, diagnosis and treatment of lipid disorders 
rests on family physicians (primary care physi-
cians) [7]. The prophylactic and therapeutic man-
agement should always involve improvements 
in lifestyle and eating habits, which may require 
consultations with a dietician [8]. The treatment 
of dyslipidaemias requires cooperation between 
primary care physicians and medical specialists 
(internists, cardiologists, diabetologists, nephrolo-
gists and neurologists). 
Screening for dyslipidaemias should be per-
formed in individuals with at least one risk factor 
for cardiovascular diseases (e.g. arterial hyper-
tension, obesity, nicotine dependence syndrome, 
adverse family history) and in all men > 40 years 
of age and women > 50 years of age, post-meno-
pausal women, women with gestational diabetes 
and gestational hypertension, individuals infected 
with HIV or undergoing HAART, men with erectile 
dysfunction as well as in all cases accompanied by 
symptoms indicative of CVD. 
Regular lipid profiling should be performed in 
individuals:
•	 diagnosed with cardiovascular disease,
key PoInTS To reMeMber
•	 The efficacy of dyslipidaemia treatment in 
Poland is still unsatisfactory. Data in this re-
gard collected over the past decade reveal 
discrepancies, which result in part from the 
selection of the study populations (subjects 
treated on an outpatient/inpatient basis) 
and subsequent modifications of therapeu-
tic recommendations. However, taking into 
account a  clear tendency for a  gradual re-
duction in the target concentration of LDL-C 
in consecutive guidelines, it should be con-
cluded that the treatment of dyslipidaemias 
in Poland is effective in less than a half of 
all patients.
•	 Therapeutic failure is partially a  conse-
quence of the nature of dyslipidaemia: the 
condition is clinically silent and chronic, 
which has a negative impact on compliance, 
adherence and persistence. With regard to 
patients, it appears that the main cause of 
non-adherence is the fact that they are not 
aware of the chronic nature of dyslipidae-
mia and have no awareness of the direct 
correlation existing between the efficacy (or 
inefficacy) of dyslipidaemia therapy and the 
actual risk of myocardial infarction, stroke or 
fatal cardiovascular disease.
•	 Finally, therapeutic inertia remains a serious 
problem among physicians who have unjus-
tified concerns both about using statins in 
a  strength and dose appropriate for thera-
peutic targets, and about using combined 
therapy. A  common negative consequence 
of inappropriate approaches adopted by pa-
tients and physicians is a persistently high 
rate of treatment discontinuation.
•	 Taking into account the prevalence of dyslip-
idaemia and its direct association with the 
prevalence of cardiovascular system disor-
ders, the efficacy of dyslipidaemia therapy is 
a very important public health problem. 
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•	 diagnosed with familial hypercholesterolaemia,
•	 with a  family history of premature cardiovas-
cular diseases,
•	 diagnosed with diabetes,
•	 diagnosed with chronic kidney disease,
•	 diagnosed with autoimmune, rheumatic and 
inflammatory diseases,
•	 in chronic smokers,
•	 infected with HIV or undergoing HAART.
The cooperation between family (primary care) 
physicians and specialists in the diagnosis and 
treatment of dyslipidaemias should focus, first 
and foremost, on the aspects listed below: (1) 
suspicion or diagnosis of familial hypercholestero-
laemia (and other genetic diseases accompanied 
by severe lipid disorders), (2) statin intolerance 
in patients at a risk of myopathy, hepatopathy or 
diabetes, (3) severe hypercholesterolaemia/dys-
lipidaemia resistant to treatment with available 
drugs, (4) severe hypertriglyceridaemia, (5) initia-
tion of dyslipidaemia in children.
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